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ABSTRACT 
 
DNA double strand breaks (DSBs) pose a serious threat to cellular and organism well-being. In 
response to DSBs, MRE11/RAD50/NBS1 (MRN) initiates DNA repair and facilitates signaling 
via ataxia-telangiectasia mutated (ATM) and ataxia-telangiectasia- and rad3-related (ATR) 
kinases. Though alteration of any one of several MRE11 protein interaction partners contributes 
to human genetic disease and/or carcinogenesis, the role MRE11A mutation plays in these 
processes remains unclear. I have set out to clarify this role with potential implications in cancer 
prevention, prognostication, and treatment. 
I studied four human disease-associated MRE11 mutants. Mutants had altered phosphodiesterase 
domain (MRE11 W243R (ATLD17) and MRE11 Del340-366 (ASM)), glycine-arginine-rich 
(GAR) motif (MRE11 R572Q (GRM)), or cyclin-dependent kinase (CDK) 2-interacting motif 
(MRE11 R633X (ATLD1)). Murine versions of the mutants were expressed to physiologic 
MRE11 levels in murine embryonic fibroblasts, and conditional deletion abolished wild-type 
MRE11 expression. In this context, I assessed the mutant proteins’ abilities to facilitate DSB 
response (DSBR) signaling. 
Each cancer-associated mutant had distinct effects on ionizing radiation (IR)-induced DSBR. 
ATLD17, ASM, and GRM were defective in facilitating ATM, ATM and ATR, and ATR 
activity, respectively. Only the impact of ASM obviously disabled the G2/M checkpoint. No 
defect in ATLD1-facilitated kinase activity was detected. Whereas ATLD17- and ASM-
associated deficits appeared to be attributable to varying disruptions in the MRN complex, no 
such disruptions were evident with GRM or ATLD1.  
MRE11 functional roles clarified include those of the phosphodiesterase domain and 
homodimerization motif in ATM activation and those of the MRE11 GAR and CDK2-interacting 
motifs in DSBR signaling. Physiologic MRE11 levels were found to be crucial for optimal 
DSBR signaling. Because our findings concern the influences of MRE11 protein levels, protein 
folding, protein-protein interactions, and post-translational modifications on fundamental cellular 
processes, these findings may broadly inform understanding of MRE11 and protein complexes 
containing MRE11 in normal and disease states.
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CHAPTER 1: INTRODUCTION 
 
1.1: Damage happens  
DNA damage is commonplace; each human cell sustains on the order of 10
4
-10
6
 lesions per day, 
yet cellular and organism viability rely upon maintenance of genomic integrity for survival and 
reproduction [1]. Damage can arise from endogenous processes. DNA is subject to nonenzymatic 
alkylation, or DNA can undergo uncatalyzed hydrolytic production of deaminated bases or 
abasic sites [2-6]. Cellular respiration gives rise to an abundance of intracellular reactive oxygen 
species (ROS) [7]. Some ROS invariably make it to the DNA and cause damage. ROS - along 
with nitrogen species - are made even more abundant during inflammation [8]. Additionally, 
DNA is damage-prone during replication. In part because ribonucleotides are far more prevalent 
than deoxyribonucleotides – even during DNA replication, ribonucleotides are often 
misincorporated [9]. This constitutes by far the most common cause of endogenous nucleotide 
base lesion in proliferating cells. After being incorporated, ribonucleotides are more susceptible 
than their deoxy counterparts to undergoing hydrolysis to produce SSBs [10]. Additionally, 
deoxyribonucleotides can be misincorporated during replication, resulting in base mismatches 
[11]. Replication of highly repetitive regions of DNA can be problematic and - through processes 
such as polymerase slippage - can result in addition to or deletion of repetitive elements [12]. In 
addition, abortive topoisomerase activity can produce SSBs or DNA double strand breaks 
(DSBs) that require additional cell machinery to be fixed [13-16]. DNA damage can also be 
programmed. Lymphocyte development requires DNA breaks or alteration during V(D)J 
recombination, class-switch recombination, and somatic hypermutation [17]. Moreover, DNA 
breaks are required for crossing over during meiosis in gametes [18]. 
The genome is under constant assault from exogenous agents. Ultraviolet radiation (UV) is 
ubiquitous and is capable of producing 10
5
 lesions per exposed cell per hour [19]. UV light 
produces cyclobutane dimers and pyrimidine-(6-4)-pyrimidone photoproducts [20]. Exposure to 
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chemicals, such as those in tobacco products, heterocyclic amines in over-cooked meats, and 
aflatoxins in moldy food, can result in DNA adduct formation [21]. Infectious agents often cause 
DNA damage indirectly through incitement of inflammation and replication stress as well as 
interference with DNA maintenance machinery, but they can also directly cause damage – e.g. 
via viral integration [22]. Iatrogenic DNA damage arises from use of cancer chemotherapeutic 
agents including alkylating agents, antimetabolites, and topoisomerase inhibitors [23-25]. 
Ionizing radiation (IR) is another exogenous cause of DNA damage. IR can arise from natural 
sources or iatrogenically. Naturally occurring radioisotopes can decay into radon, which 
accumulates in some basements and exposure to which has been associated with lung cancer 
[26]. Iatrogenic sources of IR include computed tomography scans, plain film X-rays, 
fluoroscopy, and nuclear medical imaging using 
123
I, 
99m
Tc, and 
18
F [27,28]. Though DSBs are 
not necessarily the most common type of damage caused by IR, DSBs are a particularly 
cytotoxic result of IR exposure [29]. Because of this trait, IR is often used therapeutically [30]. 
131
I is use to treat benign and malignant thyroid diseases. Common cancer treatments include 
photon therapy and brachytherapy using 
137
Cs, 
60
Co, 
192
Ir, 
125
I, 
103
Pd, or 
106
Ru. Finally, nuclear 
weapons use at Hiroshima, Nagasaki, and test sites around the world and nuclear meltdowns the 
likes of Chernobyl and Fukushima serve as tangible if somber reminders of the damaging powers 
of ionizing radiation. 
 
1.2: The DNA damage response (DDR) 
The DNA damage response (DDR) encompasses DNA lesion detection, signaling of lesion 
presence, and mediation of DNA repair.  
DNA repair, overview 
To deal with the myriad DNA lesions, cells have evolved a diverse array of complementary and 
sometimes overlapping DNA repair pathways. O
6
-alkyguanines undergo direct reversal, i.e. 
dealkylation [31]. The mismatch repair machinery detects DNA mismatches and 
insertion/deletion loops and performs nicking of a single strand; the mismatch is subsequently 
resolved by nuclease, polymerase, and ligase activities [32]. Abnormal DNA bases and simple 
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base adducts may be handled by base excision repair (BER) which begins with glycolytic base 
removal followed by nuclease, polymerase, and ligase activities [33]. Single strand breaks – such 
as those which might occur with backbone hydrolysis following ribonucleotide misincorporation, 
oxidative damage, and abortive topoisomerase I activity commonly feed into the BER pathways. 
Helix-distorting base lesions, e.g. bulky base adducts and UV photoproducts, undergo nucleotide 
excision repair (NER) [34]. Difficulty transcribing across lesions can result in transcription-
coupled NER. A global NER pathway also exists. In either case, nucleolytic activity results in 
excision of 22-30 bases which is followed by polymerase and ligase activity. Replication fork 
blockage can be bypassed by translesion synthesis polymerases [35].  
Double strand break (DSB) repair occurs by one of two types of mechanisms: non-homologous 
end-joining (NHEJ) and homology-directed repair (HDR) (Figure 1) [36,37]. Classical NHEJ (C-
NHEJ) involves detection by the highly abundant KU70/80 complex, signal transduction by 
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activation and activity, Artemis 
nuclease, X-ray repair cross-complimenting protein (XRCC) 4, ligase (LIG) 4, and XRCC4-like 
factor (XLF). KU70/80 and XRCC4/LIG4 are considered the NHEJ core and are sufficient for 
blunt end ligation. DNA-PKcs and Artemis are responsible for processing non-blunt ends prior to 
ligation. Unlike C-NHEJ, alternative end-joining (A-EJ) remains poorly defined. Though no 
proteins have been identified as functioning exclusively in A-EJ, several proteins - including 
ADP-ribosyl transferases (ARTs, more commonly known as PARPs), meiotic recombination 
(MRE) 11, C-terminal binding protein-interacting protein (CTIP), Werner syndrome helicase 
(WRN), LIG1, and LIG3 - have been implicated in A-EJ. C-NHEJ and A-EJ – but especially the 
latter - are considered error-prone. NHEJ can occur during any phase of the cell cycle but 
especially predominates during G1/G0, and C-NHEJ is relatively fast and efficient. Consequently, 
C-NHEJ is the predominate means of general DSB repair in mammalian cells. V(D)J 
rearrangements and class-switch recombination (CSR) are also catalyzed by C-NHEJ and C-
NHEJ or A-EJ, respectively [38]. 
Homology-directed repair includes homologous recombination (HR) [37]. For HR, a complex of 
MRE11, RAD50, and Nijmegen breakage syndrome (NBS) 1 (MRN) and CTIP promote 
resection to yield ssDNA intermediates. RAD51, breast and ovarian cancer susceptibility protein 
(BRCA) 1, and BRCA2 are involved in invasion of the resulting 3ʹ-ssDNA into the homologous 
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sister chromatid sequence. Polymerases, nucleases, helicases, and ligase all subsequently 
cooperate in substrate resolution and ligation. HR results in high-fidelity repair. HR is restricted 
to S and G2 phases of the cell cycle, when a sister chromatid is present; during that time, HR is 
the predominant general DSB repair pathway. Components of the HR machinery are also 
involved in DNA replication restart at stalled replication forks, resolution of inter-strand cross-
links, A-EJ, and meiotic recombination. 
 
Figure 1: DNA double strand break repair pathways, overview 
 
 
DNA damage response signaling, overview 
In addition to activating various DNA repair pathways, DNA breaks can activate apical 
phosphatidylinositol 3-kinase-related kinases: DNA-PKcs, ataxia-telangiectasia mutated (ATM), 
and/or ataxia telangiectasia- and rad3-related (ATR) (Figure 2) [39]. After DSBs are sensed by 
KU70/80 or MRN, DNA-PKcs or ATM is activated, respectively. DSB resection results in 
replication protein A (RPA)-coated ssDNA, ATR interacting protein (ATRIP) and ATR 
recruitment, and ATR activation [40,41]. Following activation, these kinases target proteins 
containing their (S/T)Q consensus sequence [42-44]. Amongst ATR and ATM targets are 
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checkpoint kinase (CHK) 1 and CHK2 which together regulate cyclin-dependent (CDK) kinase 
activity [45-48]. DNA damage-induced CDK inhibition results in delays at G1/S, intra-S, and 
G2/M checkpoints which allows cells more time to repair damaged DNA [49]. Apical kinases 
also activate DNA repair: They induce DNA repair protein activity either through transcriptional 
upregulation or post-translational modification, and they promote recruitment of factors for 
damage repair. Recent studies point to the vastness of the ATM and ATR kinomes, suggesting 
these kinases actually regulate many other cellular processes [44].  
Following successful repair, DDR signaling activates its own downregulation [50-54]. If damage 
persists, chronic DDR can often activate cellular senescence or apoptosis [55]. Erroneous DNA 
repair potentially results in a loss of cell functioning- including the ability to accurately repair 
future DNA lesions – and other oncogenic changes [56].  
 
Figure 2: DNA double-strand break response signaling, overview 
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1.3: The MRE11/RAD50/NBS1 (MRN) complex: A key regulator of double strand break 
response signaling and repair 
The MRN complex is a key mediator of the cellular DSB response (DSBR). MRN senses DSBs, 
activates the ATM and ATR apical kinases, mediates homology-directed repair during S and G2 
phases of the cell cycle and meiosis, promotes DSB resection, and serves a broader role in 
tethering DNA ends together [57].  
MRE11/RAD50/NBS1 structure 
MRE11 and RAD50 are highly conserved; orthologues are found in bacteriophages, eubacteria, 
archaea, and eukarya. NBS1 is part of a family limited to eukarya which includes Xrs2 in the 
budding yeast Saccharomyces cerevisiae [58]. 
MRE11 consists of an ordered and conserved N-terminal phosphodiesterase domain and a 
disordered and somewhat less conserved C-terminus (Figure 3A) [59]. The phosphodiesterase 
domain includes the nuclease or catalytic domain and the capping domain. The nuclease domain 
includes five nuclease motifs. These nuclease motifs contain residues responsible for 
coordination of 2 Mn
2+
 ions per nuclease active site. A mechanism of nucleolytic cleavage has 
been proposed based on archaea Pyrococcus furiosus Mre11-nucleotide structures [60-62]. The 
active site residues directly involved in Mn
2+
 coordination and transition state stabilization are 
conserved between archaea and humans, suggesting the same mechanism may be applicable to 
Homo sapiens MRE11 [59]. While one Mn
2+
 ion stabilizes the substrate DNA backbone, the 
other Mn
2+
 ion binds the hydroxide ion nucleophile. PfMre11 H85 (HsMRE11 H129) is 
presumed to be involved in stabilization of the pentacovalent transition state and proton donation 
to the 3ʹ-OH leaving group.  
The MRE11 nuclease domain is also involved in homodimer formation. Though many residues 
involved formation of the hydrophobic dimer interaction sites are conserved between eukarya 
and prokarya, the structures are otherwise divergent. The primary dimerization interface in 
prokaryotic Mre11 is a four-helix bundle [61,63,64]. In contrast, the primary dimerization 
interface of HsMRE11 consist of interaction of an extend α2-β3 latching loop – not found in 
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prokarya – and helices H2 and H3 of the opposite protomer [59]. Together this loop and these 
helices have extensive hydrophobic interactions, a water-mediate H-bond, and a disulfide bond. 
Another HsMRE11 dimerization interface occurs by packing of the β3-α3 loop of one protomer 
with the S4-S5 loop – which is much shorter than that found in prokaryotic Mre11 - of the 
opposite protomer.  
PfMre11 co-crystallization with synaptic and branched DNA structures revealed six binding 
loops in the PfMre11 phosphodiesterase domain, and DNA-interacting residues in five of these 
six loops are conserved between humans and P. furiosus [62]. However, when synaptic DNA 
was modeled onto HsMRE11, a much different DNA binding configuration was predicted [59]. 
Furthermore, branched DNA was sterically hindered from binding to HsMRE11 in a manner 
similar to that seen for PfMre11. These modeling studies, the increased compaction of the 
HsMRE11 phosphodiesterase domain, and the differences in homodimer configuration between 
PfMre11 and HsMRE11 together suggest that DNA binding modes are quite different for 
HsMRE11 and prokaryotic Mre11. The disordered mammalian MRE11 C-terminus includes a 
glycine-arginine-rich (GAR) motif – which has no equivalent in prokaryotic Mre11 – that has 
been implicated in DNA binding [65]. Other C-terminal motifs have also been implicated [66]. 
However, the nature of mammalian MRE11 DNA binding is otherwise poorly understood. 
The MRE11 C-terminus may also be involved in binding to RAD50. The prokaryotic Mre11 C-
terminus and capping domain are critical for interaction with the Rad50 coiled-coil and ATPase 
domains, respectively [63,67,68]. The Mre11 C-terminus forms a helix-loop-helix motif that fits 
orthogonally across the end of the Rad50 coiled-coil domain. Conservation of Mre11 C-terminal 
residues suggests the mammalian MRE11 C-terminus could be similarly involved though this 
interaction remains to be defined.  
In addition to potentially being involved in DNA and RAD50 binding, the MRE11 C-terminus 
may serve as a flexible tether to mediate other MRE11-protein interactions. MRE11 has been 
recently shown to interact with CDK2 and enable CDK2-mediate CTIP phosphorylation and 
activity [69].  
MRE11 and RAD50 form are able to form a heterotetrameric DNA binding and processing core 
[61,70]. RAD50 consists of an ATPase domain connected via a long coiled-coil domain to a 
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Zn
2+
-coordinating hook domain (Figure 3B) [71]. The hook domain can either contribute to 
RAD50 homodimerization within an M2R2 complex or interact with other M2R2 complexes to 
bridge DNA ends as far away as 1200Å [70,72]. The coiled-coil domains are involved in MRE11 
binding, DNA binding, and communication of hook domain and ATPase domain binding 
statuses across the complex. In addition to hydrolyzing ATP, the ATPase domain interacts with 
MRE11 and is the primary domain responsible for RAD50 homodimerization. 
NBS1 includes an N-terminal Forkhead homology (FHA) domain and tandem BRCA C-terminal 
(BRCT) domains (Figure 3C). These domains are responsible for interaction with DSBR 
phosphoproteins such as CTIP and mediator of DNA damage checkpoint (MDC) 1. Like 
MRE11, NBS1 has a disordered, flexible C-terminus. The NBS1 C-terminus includes an MRE11 
binding motif and an ATM binding motif. The fission yeast Schizosaccharomyces pombe Nbs1 
Mre11 binding motif has been shown to interact with the SpMre11 capping domain and latching 
loops [73]. This interaction is asymmetrical in nature with only one SpNbs1 molecule making 
contacts with the latching loops of both SpMre11 protomers. Disruption of the SpMre11 or 
HsMRE11 latching loops was found to compromise interaction with SpNbs1 or HsNBS1, 
respectively, consistent with the importance of the latching loops in MRE11-NBS1 interaction 
[59,73]. 
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Figure 3: MRE11, RAD50, and NBS1 structures 
 
 
MRE11/RAD50/NBS1 in DNA metabolism and repair 
MRN facilitates general DSB repair through enzymatic and architectural activities. MRE11 and 
MRN possess Mn
2+
-dependent 3ʹ-5ʹ exonuclease, ssDNA endonuclease, and hairpin opening 
activities in vitro [74,75]. Paradoxically, this nuclease activity is required for efficient 
completion of HR, which requires production of a 3ʹ tail for strand invasion [76]. MRN-CTIP 
nuclease activity appears to be involved in nicking DNA up to a few hundred bases away from 
DSBs and thereby provides sites for other nucleases, e.g. EXO1 or DNA2, to complete DNA 
resection and produce a 3ʹ tail [77,78]. Meanwhile, MRN is able to tether DNA ends over short 
or long distances so that they may eventually be rejoined [79]. Part of MRN’s usefulness in 
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initiation of DSB resection may lie in its ability to cleave 3ʹ adducts from DNA ends [80]. 
Hence, abortive topoisomerase II activity can be repaired with the help of MRN nuclease 
activity. MRN processing could also work to favor HR over C-NHEJ. DNA-PK favors binding 
to dsDNA ends, so DNA end processing could discourage DNA-PK binding and C-NHEJ. The 
functions of MRN in HR promotion are critical for cellular homeostasis. HR is critical during 
proliferation with HR defects resulting in impaired development and stem cell function [81]. 
Furthermore, accumulation of unrepaired DSBs is associated with cellular senescence or loss and 
aging [82]. 
MRN nuclease and tethering activities also appear to play roles in facilitating NHEJ. B cells 
expressing the nuclease-dead MRE11 H129N mutant were found to be defective in class switch 
recombination (CSR), an NHEJ process [38]. The loss of MRN further decreased CSR 
efficiency, consistent with MRN tethering of DSBs being important for general DSB repair. 
MRN mediation of class switch recombination and NBS1 and ATM promotion of V(D)J 
rearrangement collectively promote effective adaptive immunity. 
In addition to its role in general DSB repair, MRN participates in DSB prevention. MRN 
facilitates resection at stalled replication forks to prevent replication fork collapse [83]. Also, 
MRN is able to cleave 3ʹ-phosphotyrosyl bonds and thereby prevent abortive topoisomerase I 
activity from being encountered by a replication fork and becoming a DSB [84].  
Furthermore, MRN is involved in telomere homeostasis [85-87]. MRN binds to telomeres in S 
and G2 phases of the cell cycle where it could be involved in production of leading strand 3ʹ 
overhangs. With the assistance of other components of the HR machinery, these overhangs can 
subsequently be used to form t-loops. T-loop formation, in turn, prevents recognition of 
chromosome ends as DSBs. In this manner, MRN and ATM activity prevent NHEJ-mediated 
telomeric fusions. However, these proteins can also support neoplasia through mediation of HR-
based alternative lengthening of telomeres. 
DNA processing by MRN is also required in meiosis [88,89]. During initiation of crossing over, 
the topoisomerase II-like enzyme SPO11 creates DSBs and remains covalently attached to the 
DNA ends. MRN is required for SPO11 removal and production of ssDNA. The complete set of 
HR machinery, including ATM, participates in progression of HR during meiosis. Additionally, 
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evidence exists that suggests MRN tethering is required for SPO11-mediated DSB induction, 
reinforcing the importance of MRN tethering [90]. 
MRE11/RAD50/NBS1 in signaling 
MRN plays a crucial role in DSB signal transduction. MRN mediates ATM kinase recruitment to 
DSBs [91,92]. Upon ATM recruitment, ATM autophosphorylates, monomerizes, and is 
activated. ATM targets include the CHK2 kinase, the tumor suppressor p53, histone H2AX, 
MRN, CTIP, and KRAB-interacting protein (KAP) 1. MRN also indirectly activates ATR and 
CHK1 through its activities promoting DNA resection. These events and others combine to delay 
progression through the cell cycle, promote repair, and – if necessary – trigger senescence or 
apoptosis.  
The NBS1 C-terminus has been reported to be sufficient and necessary for ATM interaction; 
however, NBS1 lacking an MRE11 binding motif showed decreased interaction with ATM [40]. 
This observation is consistent with ATM relying upon multiple contacts with MRN for activation 
and activity. Furthermore, absence of an NBS1 C-terminus was associated with intact ionizing 
radiation (IR)-induced ATM autophosphorylation but deficiencies in IR-induced CHK2 and p53 
phosphorylation, abrogated γH2AX foci formation, radiosensitivity, and radioresistant DNA 
synthesis. Moreover, MR was sufficient for ATM interaction and activation in biochemical 
assays while the NBS1 N-terminus and MRE11 C-terminus appeared important for MRN-ATM 
interaction [91]. These observations are consistent with the NBS1 C-terminus being important 
for directing ATM activity towards certain substrates but not necessarily for ATM activation per 
se. Therefore, contacts between ATM and MRN sites other than the NBS1 C-terminal ATM 
interacting motif are required for ATM activation in cells. 
ATM activity is important for DNA damage-induced cell cycle checkpoint activation, 
senescence, and apoptosis. ATM can target and activate the CHK2 [46]. CHK2 phosphorylates 
the CDK phosphatase CDC25. This phosphatase is required for CDK-cyclin complex activity, 
and inhibitory phosphorylation of CDC25 prevents CDK-cyclin activity and cell cycle 
progression. ATM and CHK2 both target the tumor suppressor p53. P53 phosphorylation 
activates transcriptional programs specifying DNA repair and cell cycle arrest. Chronic DSBR 
signaling can prolong p53 activation and result in senescence or apoptosis [55,93,94]. 
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Another ATM target is the histone variant H2AX [95]. As a result, γH2AX is able to recruit 
mediator of DNA damage checkpoint (MDC) 1. MDC1 is able to recruit additional MRN and 
ATM thereby closing a positive feedback loop. MDC1-null cells have normal levels of ATM 
autophosphorylation but still display evidence of defective DSBR signaling suggesting that 
MDC1-mediated recruitment is required for appropriate directing of ATM activity [96]. MRN 
recruitment by MDC1 depends upon MDC1 phosphosite interaction with the NBS1 N-terminal 
FHA and BRCT domains [97], and disruption of the interaction results in checkpoint defects 
consistent with its importance in checkpoint activation [98]. 
One critical target of ATM signaling is MRN itself [44,99-105]. ATM mediates MRN 
phosphorylation and affects MRN localization, protein-protein interactions, and DNA repair 
function. ATM-dependent NBS1 phosphorylation is important for proper ATM targeting of 
SMC1 and CHK2, intra-S phase checkpoint activation, and radioresistance [105-109]. RAD50 
S635 phosphorylation dispensable for MRN complex formation and ATM activation but not 
ATM activity towards SMC1, radioresistance, DSB repair, and S phase checkpoint activation 
[110]. Though MRE11 is also an ATM substrate, the functional significance of this relationship 
has not yet been determined. 
ATM targeting of CTIP modulates DNA repair. CTIP participates in and has been proposed to 
modulate choice between HDR and A-EJ [111-114]. CTIP phosphorylation, levels, and complex 
formation with MRN and BRCA1 are controlled by CDK activity in a cell cycle-dependent 
manner (Figure 4) [115]. Following DNA damage in S or G2 phases, CTIP is phosphorylated in 
an ATM-dependent manner. Hyperphosphorylated CTIP promotes MRN-mediated DNA 
resection, BLM and EXO1 recruitment, checkpoint signaling, and homologous recombination 
[111,115]. Resected DNA is loaded with replication protein A (RPA). RPA-ssDNA recruits ATR 
along with its interacting protein ATRIP [40,41]. In this context ATR is activated. A critical 
target of ATR is checkpoint kinase (CHK) 1 [45,48,116,117]. ATR-mediated CHK1 S345 
phosphorylation is required for mitotic catastrophe avoidance and cellular viability. In fact, 
CHK1 S345A is unable to support cellular proliferation [117]. 
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Figure 4: DNA resection and repair is modulated by cell cycle- and ATM-controlled CTIP 
modification 
 
 
Condensed chromatin presents a major impediment to DNA repair. ATM acts to alleviate this 
issue through phosphorylation of the transcriptional corepressor KAP1 [118]. Under unstressed 
conditions, KAP1 activity promotes heterochromatin formation through autoSUMOylation and 
recruitment of nucleosome deacetylases, methylases, and remodelers. ATM-dependent KAP1 
S824 phosphorylation results in abrogation of KAP1-chromatin remodeler CHD3 interaction and 
chromatin relaxation [119]. 
MRE11/RAD50/NBS1 confirmation in DSB detection, signaling, and effector responses 
An integrated model of MRN as a molecular clamp has been proposed (Figure 5) [67,73,120-
122]. In it, MRN alternates between extended and compact states depending upon nucleotide and 
DNA binding status. The open configuration consists of M2R2N2 splayed such that DNA binding 
and nuclease sites are unobstructed, RAD50 coiled-coils are lax, and homodimerization is 
 14 
 
mediated through MRE11 phosphodiesterase domains and intracomplex Zn
2+
 hook interactions. 
MRN of this configuration could bind DNA ends with large covalent adducts, e.g. SPO11 or 
topoisomerase II. Recognition and processing of a DSB or DNA hairpin and ATP binding 
together promote a more compact M2R2N2 catalytic head and tighter DNA binding. RAD50 
coiled-coil domain rigidity is increased, and RAD50 Zn
2+
 hooks make intercomplex interactions 
to tether DSBs over large distances. In this closed configuration, MRE11 is sterically hindered 
from binding dsDNA, and therefore, its dsDNA exonuclease activity is stymied. On the other 
hand, MRE11 retains binding and endonuclease activities towards ssDNA and hairpins. Iterative 
ATP hydrolysis results in partial melting of dsDNA and hairpin opening. Finally, the closed form 
promotes and is promoted by tighter NBS1 binding. This configuration thereby promotes MRN-
mediated ATM activation and activity. 
 
Figure 5: An integrated model of MRE11/RAD50/NBS1 structure-function relationships 
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1.4: MRE11/RAD50/NBS1 and ATM dysfunction in human disease 
Human genetic disease 
Lesions to MRE11 or its partners have been associated with human genetic disease (Tables 1 and 
2). Biallelic hypomorphic or null mutations in ATM result in ataxia-telangiectasia (AT; MIM 
208900) [123]. AT is characterized by progressive cerebellar ataxia, oculocutaneous 
telangiectasia, immunodeficiency, radiation hypersensitivity, sterility, and marked predisposition 
to malignancy, especially lymphoreticular neoplasia. Inheritance of two hypomorphic NBN 
(NBS1) alleles causes Nijmegen breakage syndrome (NBS; MIM 251260) [124]. Like AT, NBS 
includes immunodeficiency, radiation hypersensitivity, and a marked cancer predisposition. NBS 
is distinguishable from AT by the lack of ataxia and telangiectasia and by the presence of 
microcephaly and growth retardation. Also notable is that the predisposition to malignancy is 
more marked in NBS; NBS patients have a lower age of incidence and a higher lifetime 
prevalence of cancer.  
 
Table 1: Human genetic diseases associated with MRE11 partners 
disorder
ataxia 
telangiectasia 
(AT)
Nijmegen 
breakage 
syndrome (NBS)
Nijmegen 
breakage 
syndrome-like 
disorder (NBSLD)
mutated gene ATM NBN (NBS1) RAD50
cerebellar ataxia + - +
microcephaly - + +
telangiectasia + - nr
immunodeficiency + + -
malignancy + + -
MRE11 protein wild-type wild-type wild-type
MRE11/RAD50/NBS1 levels* ++++/++++/++++ ++++/++++/+ +++/+/+
defective MRE11 IRIF formation + + +
deficiency in ATM-dep events + + +
spontaneous chromosomal 
aberrations
+ + +
cellular IR hypersensitivity + + +
nr=not reported
*: +=very low, ++=low, +++=moderate, ++++=normal, +++++=high  
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Table 2: MRE11A mutation-associated human genetic diseases 
disorder
ATLD1-2, 
19-20
ATLD3-4 ATLD5-6 ATLD7-16 ATLD17-18 NBSLSM1 NBSLSM2
cerebellar ataxia + + + + + - +
microcephaly - - - ± - + +
telangiectasia - - - - - nr nr
immunodeficiency - - - - - - -
malignancy - - - - + - -
MRE11 protein R633X
N117S, 
(R571X)
T481K, 
(R571X)
W210C
W243R, 
(Δ340-366)
wild-type
wild-type, 
D113G
MRE11/RAD50/NBS1 levels* +/+/+ ++/++/+ ++/++/++ +++++/+++++/+ ++/++/+ +/+/++ +/+/++
defective MRE11 IRIF formation + + + + nr + +
deficiency in ATM-dep events + + + + + + +
spontaneous chromosomal 
aberrations
+ + - - + nr nr
cellular IR hypersensitivity + + + + nr + +
ATLD=ataxia telangiectasia-like disorder, NBSLSM=Nijmegen breakage syndrome-like severe microcephaly
nr=not reported
*: +=very low, ++=low, +++=moderate, ++++=normal, +++++=high
 
Autosomal recessive syndromes due to mutation of RAD50 or MRE11A (MRE11) appear to be 
much rarer and were more recently discovered than those caused by ATM or NBN mutation; 
therefore, the former are mostly thought of in terms of their likeness to AT or NBS. 
Hypomorphic RAD50 mutation has been associated with autosomal recessive NBS-like disorder 
(NBSLD; MIM 613078) [125]. NBSLD resembled NBS in terms of microcephaly and growth 
retardation. Unlike NBS, NBSLD was not associated with immunodeficiency or lymphoid 
malignancy, and it included uncoordinated movements and nonprogressive ataxia. Biallelic 
hypomorphic MRE11A mutation has been associated with NBS-like severe microcephaly 
(NBSLSM) though it has been more commonly associated with ataxia telangiectasia-like 
disorder (ATLD; MIM 604391) [126-132]. The former was characterized by severe 
microcephaly, developmental delay, and lack of coordination or nonprogressive ataxia without 
obvious predisposition to malignancy or immunodeficiency. ATLD is characterized by cerebellar 
ataxia and cellular genomic instability similar to but milder than that seen in classic AT. Neither 
immunodeficiency nor telangiectasia have been associated with ATLD. 
These diseases are alike in that they show neurologic phenotypes though the phenotypes appear 
to vary from those representing developmental defects - exemplified by microcephaly, for 
instance -  to those representing neurodegeneration - e.g. progressive cerebellar ataxia. Because 
HR is required for cellular proliferation and stem cell function, the developmental defects could 
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arise due to decreased HR efficiency [81,133-135]. On the other hand, the neurodegeneration 
could be due to decreased capacity to deal with the DNA damage common to terminally-
differentiated neurons. Neurons have a high rate of mitochondrial respiration and therefore 
possess high levels of ROS [136]. As a result, neurons experience a high rate of oxidative DNA 
damage. Oxidative lesions often block transcription, upon which neurons rely heavily. Hence, 
neurons without the capacity to efficiently deal with these lesions would be expected to 
experience a substantial loss of function due to inability to sustain the necessary rate of 
transcription. Moreover, the limited regenerative capacity of adult central nervous system 
neurons means there is little ability to replace underperforming neurons. Accumulation of ROS-
associated DNA lesions is associated with common neurodegeneration phenotypes, including 
Alzheimer's, Huntington's, and Parkinson's diseases [137]. ATM plays a role in the cellular 
oxidative stress response [138], and ATLD patient cerebella have been found to accumulate 
oxidized DNA species [139]. Hence, defective responses to ROS-induced DNA damage could 
contribute to the AT and ATLD neurodegeneration phenotypes. On top of increased ROS-related 
lesions, terminally-differentiated neurons are in G0. With no sister chromatids available, they 
have to rely on lower-fidelity repair of DSBs by C-NHEJ or A-EJ [81]. Because MRN and ATM 
promote these processes, their deficiency could result in decreased ability of neurons to properly 
repair DSBs. Hence, defective DSB repair could also contribute to the neurodegeneration 
phenotype seen in AT and ATLD patients. 
AT, NBS, ATLD, NBSLD, and NBSLSM are also all associated with a cellular genomic 
instability phenotype. This was typically exemplified by deficiency in ATM signaling, cell cycle 
checkpoint dysfunction, cellular radiation hypersensitivity, and spontaneous translocations of 
chromosomes 7 and 14 in circulating lymphocytes [125,126,132,140,141]. Lack of ATM or 
NBS1 especially appears to result in impaired NHEJ-mediated antigen receptor rearrangement 
[135,142]. The decrease in productive rearrangement efficiency results in decreased circulating 
lymphocytes, agammaglobulinemia, and immunodeficiency. Inefficient DSB repair also results 
in DSB persistence and misrepair. This misrepair accounts for the high levels of circulating 
lymphocytes with spontaneous translocations involving antigen receptor loci and predisposition 
to lymphomagenesis. Predisposition to infection and malignancy account for substantial disease-
associated morbidity and mortality.  
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Cancer 
Genomic instability is a characteristic of cancer and its development [19,56]. Most carcinogens 
contribute to carcinogenesis through inducing DNA mutation. Such mutations can contribute to 
tumor suppressor inactivation and proto-oncogene activation. Oncogenic replication stress can 
result in continuous genomic instability. During cancer development, DDR is selected against 
resulting in DDR defects and increased rates of mutation. In advanced cancers, cycles of 
hypoxia-normoxia may cause DNA oxidation. 
Efficient DDR is crucial to prevention of tumorigenesis. DDR is often upregulated during the 
early stages of oncogenesis [143], consistent with its role in tumor suppression. Enhanced DDR 
has been shown to protect against tumorigenesis in certain contexts [144]. On the other hand, 
inherited DDR defects can contribute to mutator phenotypes and may allow continued 
proliferation despite accumulation of DNA damage. Inherited perturbations in the DSBR 
machinery often manifest as autosomal dominant familial cancer syndromes. Lesions to the 
tumor suppressors BRCA1, BRCA2, or their partners are responsible for familial breast cancer 
syndromes [145-147]. Moreover, inheritance of a single ATM mutation appears to predispose to 
breast cancer, and NBN mutation carriers are malignancy prone [148-156]. 
Somatic disruptions of DSBR genes also play roles in sporadic malignancies. Biallelic somatic 
ATM mutations are common in certain lymphomas and leukemias [157]. Somatic disruptions of 
BRCA1/2 and their partners are even more common in tumors than their germline defects [158].  
 
1.5: Insights from murine models of MRE11/RAD50/NBS1 or ATM dysfunction 
Mice lacking any member of the MRN complex are inviable [133,134,159,160]. Conditional 
allele deletion of any of the corresponding genes in cultured cells or in vivo proliferating tissues 
results in dramatic genomic instability and cell death [133,161,162]. These observations are 
consistent with the view that MRN is required to resolve DNA replication-associated breaks via 
homology-directed recombination. It should be noted that human genetic diseases have been 
associated with MRE11A, RAD50, or NBN hypomorphism and not nullizygosity [124-
132,163,164]. Hence, nullizygosity of any of these complex components is expected to be 
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embryonic lethal in humans, and the most appropriate murine models of these disorders are those 
with Mre11a, Rad50, or Nbn hypomorphism. 
Mice expressing hypomorphic Mre11a alleles have revealed striking phenotypes. 
Mre11a
ATLD1/ATLD1
 mice expressed murinized versions of the first ATLD allele identified 
[126,165]. ATLD1 lacks the C-terminal 76 amino acid residues including the CDK2 interaction 
motif [69]. These mice appeared to reiterate the patient phenotype. They were viable and had no 
predisposition to lymphomagenesis. Mre11a
ATLD1/ATLD1
 cells exhibited DSBR signaling defects - 
including reduced ATM signaling and checkpoint deficiencies, radiation hypersensitivity, and 
genomic instability. Though M(ATLD1)RN complex stability appeared intact, complex levels 
were very low. Still unknown is whether the cellular phenotypes were due to low levels of MRN 
complex or more directly due to the lack of MRE11 C-terminus. The lack of lymphomagenesis 
despite reduced NBS1 and ATM function suggests loss of some MRE11 function requisite for 
oncogenesis. Whether the requirement is for higher MRN levels and non-C-terminus functions or 
C-terminus-specific functions remains an open question. 
A nuclease-dead Mre11a allele, Mre11a
H129N
, has also been knocked in [76]. MRE11 H129N 
supported normal levels of the MRN complex, ATM activation, and G2/M checkpoint activation 
but failed to rescue embryonic lethality, cellular proliferation, radiation and replication stress 
hypersensitivity, homology-directed repair, and genomic stability. These findings show that 
nuclease function is essential for cellular proliferation during development but dispensable for 
ATM activation. 
Mre11a
RK/RK
 mice - in which the MRE11 glycine-arginine-rich domain arginines have been 
changed to lysines - exhibited radiation hypersensitivity. MRE11 RK appeared defective in 
MRE11 DSB localization, DNA binding, exonuclease activity, and mediation of ATR activity, 
cell cycle checkpoint function, and chromosomal stability [65,166-168]. However, once again 
the MRE11 mutant levels were sub-physiologic. In this case, Mre11a
RK/RK
 cells had MRE11 RK 
levels 50% of physiologic MRE11 levels. Hence, the MRE11 RK-associated phenotypes could 
potentially be attributed to low cellular MRE11 RK levels and/or some MRE11 RK-specific 
dysfunction. 
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Mice have also been engineered to express hypomorphic Nbn. The predominant NBN mutation is 
c.657Δ5 [124,169]. Internal ribosomal entry is required to produce a hypomorphic p70 product 
with N-terminal truncation. Nbn
ΔB/ΔB
, Nbn
m/m
, and Nbn
-/-
+NBN
657Δ5
 mice were created to mimic 
this truncation [170-172]. Each mutant is associated with loss of the N-terminal FHA domain. 
Though Nbn
ΔB/ΔB
 mice only reiterated the cellular phenotypes (radiation hypersensitivity, intra-S 
and G2/M checkpoint dysfunction, and IR-induced chromosomal instability) and subfertility, 
Nbn
m/m
 and Nbn
-/-
+NBN
657Δ5
 mice also reflected other patient phenotypes (including growth 
retardation, immunodeficiency, decreased lymphocyte maturation, increased spontaneous 
chromosomal translocations, and – for Nbnm/m mice only –predisposition to lymphomagenesis). 
Nbn
m/m
 cells had intact DSB-induced ATM activation, but DSB-induced ATM activity towards 
other targets, including CHK2, was diminished in Nbn
m/m
 and Nbn
-/-
+NBN
657Δ5
 cells. This 
phenotype was partially phenocopied in cells expressing another NBS patient allele, NBN
H45A
, 
which disrupted a highly conserved NBS1 FHA domain residue [172,173]. These results are 
consistent with the NBS1 N-terminus – and the FHA domain in particular - being dispensable for 
ATM activation but essential for appropriate ATM targeting. 
Lack of the NBS1 ATM binding motif in Nbn
ΔC/ΔC
 and Nbn
tr735
 mice resulted in mild phenotypes 
[173,174]. Nbn
ΔC/ΔC
 and Nbn
tr735
 cells did not have gross defects in DSB-induced ATM 
activation or ATM activity towards CHK2. Moreover, no change in MRN levels, subcellular 
localization, or localization to DSBs was detected. However, thymocytes were defective in IR-
induced apoptosis, a very mild intra-S phase defect was detected, and ATM-dependent SMC1 
and BID phosphorylation was impaired. These results suggest the NBS1 C-terminal ATM 
interaction motif is dispensable for ATM activation but necessary for appropriate ATM-mediated 
DSBR.  
AT differs from ATLD, NBSLSM, NBLD, and NBS in that it can result from ATM nullizygosity 
as well as hypomorphism. The majority of reported AT cases have been associated with two 
ATM frameshift, nonsense, splice site, or large gene deletion mutations that resulted in loss of 
detectable protein [163,164]. Other patients had missense mutations, in-frame deletions, or 
aberrant splicing and detectable ATM by immunoblot. Atm
-/-
 mice largely reiterated the classic 
AT patient phenotype, including growth retardation, infertility, impaired lymphocyte 
development, dramatic lymphoma predisposition, and cellular genomic instability [175-177]. In 
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contrast to the patient phenotype, no cerebellar ataxia was evident. Mice expressing the 
murinized AT patient allele Atm
ΔSRI
 had a somewhat milder phenotype than nullizygous mice 
[178]. Notably, though Atm
ΔSRI
 mice were also cancer-predisposed, they outlived their 
nullizygous counterparts. The cancers to which the mice succumbed varied by genotype, too: 
While nullizygous mice uniformly died of thymic lymphoma, Atm
ΔSRI
 mice developed a variety 
of malignancies.  
In striking contrast to the viability seen in AT mouse models, ATM kinase dead mice are 
inviable [179]. Murine cells expressing kinase dead ATM displayed increased spontaneous 
genomic instability and decreased HR efficiency relative to Atm
-/-
 cells. Hence, kinase dead 
ATM appears to actually interfere with HR and maintenance of genomic integrity. 
As is seen in humans, mice with heterozygosity in DSB repair components are cancer 
predisposed. Mice with Nbn heterozygosity or hypomorphism are predisposed to oncogenesis 
[171,180]. Mice carrying one hypomorphic Atm allele are cancer-predisposed [181] as are Ctip
+/-
 
mice [182]. These results support the importance of DSB repair machinery component gene 
dosage in tumor suppression. 
 
1.6: MRE11A mutation and oncogenesis 
Cancer-associated DSBR alterations can be exploited for prognostic and therapeutic purposes. 
For example, higher tumor MRN complex levels have been associated with better response to 
radiotherapy and better prognosis [183-186]. Hence, knowledge of tumor MRN levels could 
inform prognostication and treatment choice. Furthermore, cancer-specific DSBR alterations can 
be used for development of therapeutic targeting strategies; this point is well-illustrated by the 
success of PARP inhibitors against tumors with BRCA1 or BRCA2 deficiency [187,188].  
Despite the importance of the DSBR in cancer predisposition, prognostication, treatment choice, 
and therapeutic development, the role of MRE11A mutations in carcinogenesis remains poorly 
understood. MRE11 participates in the activation of several tumor suppressors and is frequently 
downregulated in malignancies [186,189-192]; however, an abundance of evidence suggests 
MRE11 is not a simple tumor suppressor. When MRE11A is altered in malignancies, a wild-type 
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allele usually remains intact. ATLD is assumed to be a cancer-prone syndrome; however, cancer 
has only been associated with a small subset of reported ATLD patients [126-130]. Moreover, 
Mre11a
ATLD1/ATLD1
 mice are not predisposed to the development of lymphoma - the malignancy 
to which AT and NBS patients are most markedly predisposed [165]. Organism viability and 
normal cellular proliferation require MRE11 nuclease activity [76], suggesting MRE11 may be 
required for carcinogenesis as well.  Additionally, many human genetic diseases resulting from 
hypomorphic mutations in the DSBR machinery do not appear to feature cancer predisposition. 
RAD50, ATR, or CTIP (RBBP8) mutations have been associated with the autosomal recessive 
NBS-like disorder (MIM 613078) [125], Seckel syndrome (MIM 210600) [193], or Jawad 
syndrome (MIM 251255) [125,194], yet none of these syndromes have been linked to gross 
cancer predisposition. 
We set out to help clarify the role of MRE11A mutation in carcinogenesis. To this end, the major 
impacts of previously reported MRE11A mutations were sought. A few mutants were found to 
have distinct deficits in apical kinase activation. Because of the centrality of MRN complex 
stability to many well-recognized MRE11 functions, including apical kinase activation, mutants’ 
abilities to complex were also assessed. For two mutants, MRN complex instability could 
explain the signaling defects observed. These findings provide new insight into MRN function 
and human disease pathogenesis and treatment.  
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CHAPTER 2: RESULTS 
 
2.1: Meta-analysis of disease-associated MRE11A mutations 
Several categories of MRE11A mutation were uncovered. Most common were loss of nucleotides 
from the accessory splice signal upstream of exon 5 [191,192,195-202]. Shortening of the poly-T 
tract in microsatellite instable cells lines and primary tumor cells was linked to exon 5 skipping 
and decreased MRE11 expression [191]. A few other mutations were associated with aberrant 
MRE11A splicing [129,132]. One such mutation, c.338A>G, was also associated with exon 5 
skipping and a small amount of full length transcript [132]. The resulting mRNAs potentially 
encoded F106QfsX10 or D113G, respectively. Exon 7 was reported to be skipped more 
frequently in the context of point mutations at the exon 7-intron 7 border – c.658A>C and 
c.659+1G>A [132]. The resulting mRNA potentially encoded MRE11 S183VfsX31 though none 
of this species was detected. C.1098+5G>A was reported in an allele that produced MRE11A 
mRNA lacking exon 10 [129]. This loss of 81 bp maintained downstream codons in frame. 
Hence, the mRNA potentially encoded MRE11 Δ340-366 though this species did not appear to 
have been detected. In rare instances, MRE11A was amplified [203]. More commonly, MRE11A 
was deleted [186,204]. MRE11A missense and nonsense mutations were not obviously clustered 
(Figure 6) [129,130,205-210]. Mutations were distributed both within the N-terminal 
phosphodiesterase domain and the C-terminal region.  
MRE11A mutations arose in a variety of contexts. Twenty ATLD patients have been reported 
thus far who inherited some combination of missense and nonsense mutations. A couple of these 
mutants, W243R and R633X, along with a few additional mutants were associated with familial 
cancer syndromes when inherited along with a wild-type allele. Several somatic missense and 
nonsense mutations were found in spontaneous malignancies. Microsatellite instable cancer cells 
were found to have MRE11A exon 5 skipping and reduced MRE11 levels. Two NBS-like severe 
microcephaly patients were each found to have inherited two miss-splicing alleles.  
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Figure 6: MRE11 mutant meta-analysis results 
 
 
2.2: MRE11 mutant selection 
We sought to determine how select cancer-associated MRE11A mutations (Figure 7A) impacted 
MRE11 function [129,205,207]. Alleles encoding ataxia-telangiectasia-like disorder 17/18 
(ATLD17) and an alternative splice mutant (ASM) were found in two brothers with ATLD who 
succumbed to pulmonary adenocarcinoma at the ages of 16 and 9 years [129]. These two mutants 
were interesting for several reasons. Until report of these brothers, no association between ATLD 
and cancer had been reported. Also, the young age of incidence of pulmonary adenocarcinoma – 
a disease of old age [211] – in carriers of both mutations suggests a marked genetic cancer 
predisposition. Furthermore, the substitution in ATLD17 occurred at a highly conserved residue 
– W243 – near motif IV of the phosphodiesterase domain (Figure 7B). This motif contains Mn2+-
coordinating residues important for MRE11 folding and nuclease activity [59,73]. Hence, 
W243R might plausibly affect MRE11 folding and nuclease function. The other MRE11A allele 
of these brothers contained an intronic mutation, c.1098+5G>A, and encoded mRNA lacking 
exon 10. This mRNA could potentially give rise to a protein lacking 27 amino acid residues. 
Codons downstream of the deletion would be read in frame. The deleted residues reside in the 
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capping motif of the phosphodiesterase domain and include several conserved broadly amongst 
eukarya and even a few conserved between eukarya and prokarya.  
Mutational analysis of MRE11A in unselected primary tumors revealed a mutation encoding 
MRE11 R572Q (GRM) [205]. The mutation was identified in a heterozygous lymphoma. R572 
lies in the disordered C-terminus of MRE11 [59]; hence, no structural information is available 
for the residue. Nonetheless, R572 is in the MRE11 glycine-arginine-rich (GAR) motif, elements 
of which are conserved amongst mammals, birds, amphibians, insects, nematodes, and plants. 
Studies of MRE11 RK suggest R572Q could affect MRE11 nuclease activity, apical kinase 
activity, checkpoint activation, and genomic stability [65,166-168].  
Ataxia-telangiectasia-like 1/2 (ATLD1) was first identified in an ATLD-afflicted kindred [126]. 
MRE11A
ATLD1/ATLD1
 patients and Mre11a
ATLD1/ATLD1
 mice exhibited the cellular hallmarks of 
cancer though they did not appear to be cancer predisposed [126,165]. The lack of malignancy 
could be a consequence of very low cellular MRN levels. In contrast with MRE11A
ATLD1
 
homozygosity, MRE11A
ATLD1
 heterozygosity has been linked with cancer predisposition [207]. 
We sought to determine the functional status of ATLD1 in order to clarify its role in 
carcinogenesis and to further delineate the role of the MRE11 C-terminus in DSBR signaling. 
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Figure 7: An overview of the mutants discussed 
(A) A table summarizing the name, nickname, amino acid change, and clinical context for each 
mutant. (B) A HsMRE11 stick diagram with pertinent domains and motifs. Note that the 
phosphodiesterase domain includes both the nuclease (or catalytic) domain and the capping 
domain. Amino acid changes are labeled along with mutant aliases and associated human 
diseases. Alignments of the residues surrounding the mutant sites are also shown.  
 
 
2.3: Mutant-expressing MEF creation and validation 
SV40 large T antigen immortalized Mre11a
cond/Δ
 murine embryonic fibroblasts (MEFs) [76] 
were transfected with pEF6-Mre11a constructs encoding mutants of interest, clones were 
isolated, and the remaining endogenous allele was deleted by adeno-cre treatment to yield 
mutant-expressing MEFs. Mutant-expressing clones with at least physiologic levels of MRE11 
A
B
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were deemed desirable to avoid low MRE11 levels as a possible confounding variable in 
characterization. Additionally, clones that allowed efficient deletion of Mre11a
cond
 were desired. 
To determine whether clones were maintaining mutant levels to at least physiologic MRE11 
levels during experiments, whole cell lysates were obtained before and after each experimental 
time period (Figure 8A). To probe for MRE11, an antibody recognizing the residues around 
HsMRE11 K496 was used. This region of the protein was not mutated in any mutants; hence, we 
had no a priori reason to think that antibody-MRE11 affinity would vary between wild-type 
MRE11 and any of the mutants. Each MRE11-expressing clone chosen for characterization 
possessed at least physiologic MRE11 levels (Figure 8B). The loss of a wild-type MRE11 band 
in empty-vector controls and ASM and ATLD1 clones was consistent with efficient deletion of 
the remaining endogenous Mre11a
cond
. However, for clones with missense mutants, the MRE11 
type remained undetermined by MRE11 immunoblot alone. Untagged proteins were expressed 
exogenously in order to avoid disruption of any MRE11-protein interactions [69]. As such, 
MRE11 type in these mutants was monitored indirectly by determining Mre11a mRNA type. An 
RT-PCR strategy was designed to amplify only Mre11a mRNA encoding functional protein 
(Figure 8C). Bands were only detected with the use of reverse transcriptase, consistent with these 
bands representing the amplification of Mre11a mRNA rather than pEF6-Mre11a DNA. Sanger 
sequencing of cDNA from ATLD17-, ASM-, and GRM-expressing clones revealed little wild-
type species (Figure 8D-F) consistent with mutant MRE11 being the predominant MRE11 type 
present in the cells during experimentation. 
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Figure 8: Validation of MEF mutant expression 
(A) The peri-experimental timeline. (B) Physiologic MRE11 levels are represented to the far left. 
Peri-experimental MRE11 levels are shown for each clone. Empty-vector control and ASM- or 
ATLD1-expressing clone lysates had wild-type MRE11 bands of ≥90% reduced intensity. In 
most cases, no wild-type MRE11 was detected by immunoblot of these cell lysates. The 
observations are consistent with efficient deletion of Mre11a
cond
 and loss of endogenously-
produced MRE11 prior to experimentation. Each MRE11-expressing cell line possessed at least 
physiologic levels of MRE11 at P1 and P2. (C) The RT-PCR strategy to type Mre11a mRNA of 
MRE11-expressing clones is shown (above) along with RT-PCR results (below). Bands of the 
expected sizes were detected for each clone (upper panel). No bands were detected in the 
absence of reverse transcriptase (lower panel). (D-F) Sanger sequencing of Mre11a cDNA from 
ATLD17 (D)-, ASM (E)-, or GRM (F)- expressing clones revealed little wild-type Mre11a. 
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2.4: Apical kinase activation and activity 
We chose to monitor MRN-mediated DSB-induced ATM activation and activity by measuring 
ionizing radiation (IR)-induced ATM S1987 and KAP1 S824 phosphorylation [92,212]. To 
determine the ability of each MRE11 mutant to facilitate ATR activity, IR-induced pCHK1 S345 
was measured [45].  
Controls showed robust IR-induced pKAP1 S824 and pCHK1 S345 induction in the presence of 
wild-type MRE11 (Figure 9A). On the other hand, only weak induction was observed in the 
absence of MRE11 or ATM (Figure 9A and 9B), consistent with IR-induced KAP1 S824 and 
CHK1 S345 phosphorylation being both MRE11- and ATM-dependent. 
ATLD17-expressing cells showed deficiencies in pATM and pKAP1 but not pCHK1 induction 
following IR treatment (Figure 9C and 9D). Hence, despite an upstream defect in ATM 
activation, ATLD17 appears competent enough in facilitating ATM activity to complement IR-
induced ATR activity towards CHK1 S345. Induction of pKAP1 and pCHK1 were substantially 
abrogated in ASM cells. These findings are consistent with ASM being grossly defective in 
facilitating apical kinase activity (Figure 9D).  
GRM appeared to complement ATM activation and activity (Figure 9E and 9F). MRE11 RK 
studies left open the possibility that the more subtle nature of the alteration in GRM might allow 
GRM to complement ATR activity [65]. In fact, GRM cells showed reduced CHK1 
phosphorylation post-IR. Therefore, even a subtle disruption of the GAR motif is sufficient to 
compromise ATR activity. Expression of ATLD1 to physiologic levels complemented both 
ATM and ATR activities (Figure 9F and [69]). Quantitation of pKAP1 and pCHK1 induction is 
also shown (Figure 9G through 9J). 
Dose-response and time-course studies were consistent with our findings 30 minutes after 10 Gy 
of IR. In ATLD17-expressing cells, decreased pKAP1 induction was observed following IR 
doses ranging from 0.5 Gy to 10 Gy and following recovery times from 6 minutes to 8 hours 
(Figure 10A-10C). These cells also had decreased pATM but not pCHK1 30 minutes to 8 hours 
post-IR compared to wild-type MRE11-expressing cells. Cells with ASM had reduced pKAP1 
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and pCHK1 throughout this time (Figure 10D). GRM-expressing cells complemented pATM and 
pKAP1 but had reduced pCHK1 levels during this time period (Figure 10E).  
 
Figure 9: Ionizing radiation-induced apical kinase activation and activity 
The indicated MEF clones were either left untreated or treated with 10 Gy IR and allowed to 
recover for 30 minutes. Whole cell lysates were immunoblotted for the proteins shown. GAPDH 
is a loading control. (A-F) Immunoblots are representative of at least three independent 
experiments. (A) Comparison of empty-vector and wild-type controls. Whereas only weak pKAP 
or pCHK1 induction was observed in empty-vector controls, these species were robustly induced 
in cells with wild-type MRE11. The extent of induction was similar across the range of wild-type 
MRE11 levels seen. (B) Induction of these phosphoproteins was ATM-dependent. (C,D) 
Induction of pATM and pKAP1, but not pCHK1, was partially abrogated in ATLD17-expressing 
clones. (D)ASM-expressing cells showed dramatic defects in pKAP1 and pCHK1 induction. 
(E,F) GRM expression largely complemented pATM and pKAP1 induction; however, GRM 
complemented pCHK1 induction to a much lesser extent. (F) Cells expressing ATLD1 displayed 
wild-type levels of pKAP1 and pCHK1 induction. (G-J) Quantitation of pKAP S824 and pCHK 
S345 induction by cell line (G, I) or cell type (H, J). After accounting for protein loading, 
induction was normalized to the weighted mean induction of the wild-type lines. Each bar 
represents at least three independent experiments. Error bars represent standard error of the 
mean.  
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Figure 10: Ionizing radiation-induced apical kinase activation and activity, dose-response 
and time-course studies 
(A) ATLD17 expression failed to fully complement pKAP1 induction over a wide range of IR 
doses. (B) Early pKAP1 induction was not fully complemented by ATLD17 expression. (C) 
ATLD17 expression fully complemented pCHK1 but not pATM or pKAP1 levels 30 minutes to 
8 hours post-IR. (D) ASM-associated defects in pKAP1 and pCHK1 induction persisted 30 
minutes to 8 hours post-IR. (E) Over the duration of several hours post-IR, GRM complemented 
pATM and pKAP1 induction but failed to fully complement pCHK1 induction. 
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IR-induced early G2/M checkpoint activation is MRN- and ATM-dependent [165,213]. We 
chose to measure the competency of this checkpoint in mutant-expressing cells. To do so, MEFs 
were mock-treated or treated with 10 Gy IR, and the percentages of cells positive for the mitosis-
specific phospho-histone H3 S10 marker were compared [214]. A relatively high mitotic index 
post-IR was interpreted as a G2/M checkpoint defect. Wild-type MRE11-expressing MEFs 
displayed a reduced mitotic index post-IR reflecting G2/M checkpoint activation (Figure 11A and 
11B). Relative to the wild-type control, significantly more MEFs lacking MRN or ATM were in 
mitosis after IR treatment, consistent with previous findings that the G2/M checkpoint is 
mediated by both MRN and ATM.  
Mutants defective in facilitating ATM activation would also be expected to fail to properly 
activate the G2/M checkpoint. Such a defect was observed in ASM cells; Atm
-/-
 and ASM cells 
had similar mitotic indexes post-IR. However, ATLD17, which exhibited relatively minor 
defects in facilitating apical kinase activation, was associated with decreased mitotic entry post-
IR similar to what was seen for wild-type MRE11.  
Mre11a
RK/RK 
cells are G2/M checkpoint defective post-IR, and these cells and GRM-expressing 
cells exhibit(ed) defects in ATR activity [65]. Thus, GRM was expected to be G2/M checkpoint 
defective. However, GRM cells appeared checkpoint competent. The more subtle nature of the 
substitution in GRM compared to MRE11 RK potentially accounts for the discrepancy. 
Alternatively, phenotypic dissimilarities might reflect the differences in cellular protein levels, 
with Mre11a
RK/RK 
cells having only about 50% of physiologic MRE11 levels.  
ATLD1 was previously associated with defects in apical kinase activity and G2/M checkpoint 
activation [165]. However, we found ATLD1 expression to result in wild-type levels of mitotic 
entry following IR treatment; therefore, we found no evidence of gross defect. This discrepancy 
likely reflects a difference in cellular ATLD1 levels. Our results showed no proof that the lack of 
a C-terminus hindered the ability of ATLD1 to facilitate apical kinase activity or G2/M 
checkpoint function. 
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Figure 11: G2/M checkpoint assay 
MEFs were either mock treated or treated with 10 Gy IR and allowed to recover for an hour. 
Cells were stained for the mitosis-specific p-histone H3 S10 modification. Mitotic index was 
obtained by comparison of the percentage of pH3-positive IR-treated cells to that for mock-
treated cells for each cell line. Results are shown by cell line (A) or cell type (B). A minimum of 
three independent experiments were performed for each cell line shown. Error bars represent 
standard error of the mean. At least 80% of wild-type-expressing MEFs that would otherwise be 
in mitosis were not in mitosis 1h post-IR, consistent with efficient IR-induced G2/M checkpoint 
activation. In contrast, IR treatment reduced the proportion of MRE11- or ATM-deficient cells in 
mitosis to a much lesser extent, which suggests a G2/M checkpoint defect. ATLD17-, GRM-, or 
ATLD1-expressing cells all appeared checkpoint proficient while ASM-expressing cells 
displayed a pronounced checkpoint defect. 
 
 
2.5: MRE11/RAD50/NBS1 complex stability 
Mutant-associated defects in apical kinase activity could be a consequence of MRN complex 
disruption [40,41,215,216]. MRE11 plays a role in maintaining RAD50 and NBS1 levels. ATLD 
and NBS-like severe microcephaly patient cells as well as breast cancer tissue with reduced 
MRE11 levels have reduced RAD50 and NBS1 levels [126,127,129,131,132,189]. Additionally, 
disrupted MRN complex formation has been previously detected as abnormal ratios of the 
complex components; patients with MRE11 mutations that compromise MRE11-NBS1 
interaction have reduced NBS1:MRE11 molar ratios [128,129,131]. We assessed cellular 
RAD50:MRE11 and NBS1:MRE11 molar ratios in order to determine whether they suggested 
any defect in MRN complex stability. 
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MRE11 depletion resulted in proportionally decreased RAD50 levels (Figure 12A and 12B). 
Expression of wild-type MRE11, ATLD17, ASM, GRM, or ATLD1 resulted in proportionally 
similar increases in RAD50 levels. A least-squares best fit for all MRE11 types yielded a line 
with an R
2
=0.93. RAD50:ATLD17 and RAD50:ATLD1 molar ratios were consistent with those 
found in ATLD17 and ATLD1 patient cells [126,129]. These results suggest that each mutant 
can maintain RAD50 levels to a similar extent as wild-type MRE11. Whether these observations 
are due to MRE11-mediated RAD50 stabilization through MRN complex formation is not 
entirely clear. 
Depletion of MRE11 also resulted in decreased NBS1 levels (Figures 12A and 12C). MEFs 
expressing either ATLD17 or ASM had reduced NBS1:MRE11 ratios suggestive of 
compromised ATLD17-NBS1 and ASM-NBS1 interaction. ATLD17 patient cells, which express 
the ATLD17 mutant, have reduced NBS1:MRE11 ratios [129], consistent with our findings for 
the ATLD17 mutant. In contrast, MEFs expressing GRM or ATLD1 had wild-type-like 
NBS1:MRE11 molar ratios. Therefore, MRN complex molar ratios failed to reveal any defect in 
GRM- or ATLD1-mediated complex formation. Consistent with these findings, ATLD1 patient 
cells have NBS1:MRE11 molar ratios at least those of wild-type cells [126]. The least squares fit 
for wild-type-like cell lines had a slope appreciably different from the best fit for ATLD17- or 
ASM-expressing lines. 
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Figure 12: MRE11/RAD50/NBS1 molar ratios 
(A) MRN complex component levels in empty-vector controls and wild-type MRE11- or mutant-
expressing MEF clones. Though ATLD17- and ASM-expressing cells had a wild-type-like 
RAD50:MRE11, NBS1:MRE11 was reduced in these cells. In contrast, both RAD50:MRE11 
and NBS1:MRE11 were wild-type-like in GRM- and ATLD1-expressing cells. GAPDH was 
used as a loading control. (B-C) Quantitation of cellular MRN complex component levels. 
MRE11, RAD50 (B), and NBS1 (C) levels were normalized to those in wild-expressing clone 1 
(WT 1) whole cell lysate after accounting for protein loading. Each data point represents a 
minimum of three measurements (range: 3-15, median: 5), and error bars represent standard error 
of the mean. (B) Each MRE11 type complemented RAD50 levels to a similar extent; the 
trendline shown with R
2
 value represents the least-squares best fit for all cell types. (C) ATLD17 
and ASM failed to complement NBS1 levels to the same extent as wild-type MRE11, GRM, or 
ATLD1; the trendlines shown with R
2
 values represent the least-squares best fits for wild-type-
like cell lines (EV, WT, GRM, and ATLD1) or non-wild-type-like clones (ATLD17 and ASM).  
 
 
  
 38 
 
To further investigate whether the mutants affected MRN complex stability, co-
immunoprecipitation of complex components was checked. Wild-type MRE11 pulled down and 
was pulled down by RAD50 and NBS1 (Figure 13). ATLD17 co-immunoprecipitated with 
RAD50 to a slightly lesser degree than wild-type MRE11. This defect was notably less than that 
observed with the analogous S. pombe mutant [217]. Co-IP of ATLD17 and NBS1 appeared 
substantially abrogated – similar to what was previously reported for S.pombe ATLD17 [217]. 
Similar outcomes were observed whether cells were untreated, treated with 10 Gy IR and 
allowed a 12 minute recovery, or treated with 10 Gy IR and allowed a 30 minute recovery 
(Figure 14). Because NBS1 makes contacts with both MRE11 and RAD50 [218], the defect in 
ATLD17-RAD50 co-IP may reflect both a lack of NBS1 to stabilize M(ATLD17)R and 
decreased ATLD17-NBS1 interaction. Therefore, these findings are consistent with disrupted 
M(ATLD17)RN complex stability though the low levels of NSB1 in ATLD17 cells confounded 
the interpretation of these results. 
ASM displayed dramatically reduced co-IP with RAD50 and NBS1. As was the case for 
ATLD17, the low NBS1:MRE11 ratios in ASM-expressing cells confounded the interpretation 
of the ASM co-IP results; however, the observations are consistent with a substantial defect in 
M(ASM)RN complex stability. In contrast, GRM appeared just as capable as wild-type MRE11 
of pulling down and being pulled down by RAD50 and NBS1. Hence, no defect in M(GRM)RN 
complex stability was evident by co-IP. Previous work has shown ATLD1 to stably complex by 
co-IP [69,165].  
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Figure 13: MRE11/RAD50/NBS1 co-immunoprecipitation 
MRE11, RAD50, or NBS1 were pulled down, and immunoprecipitates were immunoblotted for 
each MRN complex component. GAPDH was used as a whole cell lysate loading control. 
Results shown are representative of a minimum of three co-IPs. ATLD17 pulled down and was 
pulled down by RAD50 to a slightly lesser extent than was observed for wild-type MRE11. 
Additionally, in ATLD17-containing lysates, less NBS1 was pulled down by MRE11 or RAD50, 
and less MRE11 and RAD50 were pulled down by NBS1. The results for ASM were similar to 
those for ATLD17 except that the defect in MRE11-RAD50 co-immunoprecipitation was more 
pronounced. GRM appeared as capable as wild-type MRE11 to co-IP with RAD50 and NBS1. 
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Figure 14: M(ATLD17)RN co-immunoprecipitation did not change with ionizing radiation 
treatment. 
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2.6: MRE11 homodimerization and MRE11-NBS1 direct interaction 
Yeast two-hybrid was used to assess the abilities of each mutant to homodimerize. Yeast were 
cotransformed with vectors encoding bait (pGBK) and prey (pGAD) fusion proteins. Empty 
vectors were used as negative controls. Following cotransformation, yeast were grown on 
synthetic defined medium without leucine or tryptophan (SD-L-W) in order to select for yeast 
possessing the bait- and prey-encoding plasmids. Fusion protein interaction resulted in α-
galactosidase expression, which in turn, could be used to quantitate homodimerization (Figure 
15A). ATLD17 homodimerization was reduced compared to that for wild-type MRE11. ASM 
homodimerization was not detected. No defects in GRM or ATLD1 homodimerization were 
apparent. Homodimerization was also assayed by colony growth (Figure 15B). During the final 
round of plating, yeast clones were plated onto SD-L-W without histidine or adenine (SD-L-W-
H-ade) in order to test for fusion protein interaction and onto SD-L-W for a loading control. As 
was seen previously [69], no autoactivation was detected with MRE11 fusion proteins, and yeast 
with MRE11 in both the bait and prey showed robust growth consistent with MRE11 
homodimerization. Wild-type MRE11, GRM, and ATLD1 homodimerized to similar extents 
whereas ASM showed no evidence of homodimerization, and ATLD17 homodimerization was 
intermediate. 
Α-galactosidase assay was also used to assess direct interaction between MRE11 mutants and 
NBS1 (Figure 15C). Autoactivation was minimal. Wild-type MRE11, GRM, and ATLD1 
directly interacted with NBS1 to similar extents. A gross defect in NBS1 interaction was seen for 
ATLD17 whereas ASM-NBS1 interaction was not detected. Similar results were found by 
colony growth assay (Figure 15D). Wild-type MRE11 fusion proteins and ASM fusion proteins 
were of similar levels (Figure 16A-16C); hence, ASM fusion protein instability could not explain 
the results. Full colony growth assay plates are shown (Figure 16D and 16E). 
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Figure 15: MRE11 homodimerization and direct interaction between MRE11 and NBS1 
Yeast two-hybrid analysis was performed using pGBK and pGAD – encoding the bait and prey, 
respectively. Empty vectors were negative controls. Plasmids were selected for by culturing in 
the absence of leucine and tryptophan (SD-L-W). (A) MRE11 homodimerization by Y2H 
colorimetric assay. Bait-prey interaction resulted in α-galactosidase expression. Α-galactosidase 
activity was visualized as conversion of p-nitrophenyl-α-D-galactopyranoside (colorless) to p-
nitrophenoxide (yellow, λmax=410nm). Bait-prey combinations are shown below each bar. Each 
bar represents at least three clones per combination with at least three measurements per clone. 
Error bars represent standard error of the mean. Wild-type MRE11, GRM, and ATLD1 showed 
similar amounts of homodimerization. ATLD17 homodimerized less than wild-type MRE11, and 
ASM interaction appeared similar to that of empty vector controls. (B) MRE11 
homodimerization by Y2H colony growth assay. Bait and prey proteins are indicated on the left. 
Ten-fold serial dilution series are shown on interaction test plates (SD-L-W-H-ade, center) and 
loading control plates (SD-L-W, right). Results are representative of those for at least three 
clones per bait-prey combination. ATLD17 homodimerization was slightly abrogated. No ASM 
homodimerization was detected. No defects in GRM or ATLD1 homodimerization were 
apparent. (C) MRE11-NBS1 interaction by Y2H colorimetry. Similar to panel A in setup. 
ATLD17 showed a 54% reduction in NBS1 interaction compared to wild-type MRE11. ASM did 
not appear to interact with NBS1. GRM and ATLD1 interacted with NBS1 to the same extent as 
wild-type MRE11. (D) Bait and prey proteins (left), interaction test plates (center), and loading 
control plates (right) are shown as in panel B. The interaction of ATLD17 with NBS1 was 
slightly but consistently abrogated. ASM-NBS1 interaction was not appreciated. No defects were 
detected in GRM or ATLD1 interaction with NBS1. 
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Figure 16: MRE11 homodimerization and direct interaction with NBS1 by yeast two-
hybrid, supplemental 
(A) ASM fusion protein levels were similar to wild-type fusion protein levels. Bait and prey 
were fused to a MYC-tag or HA-tag, respectively. Tubulin was used as a loading control. (B) 
and (C) Quantitation of bait and prey levels. Fusion protein levels are presented relative to wild-
type MRE11 fusion protein levels after accounting for loading. Error bars represent the standard 
error of the mean for three clones per bait-prey combination. (D) MRE11 homodimerization 
showing full plates except for where a row or two were cropped out. (E) MRE11-NBS1 
interaction showing full plates except for where a row or two were cropped out. 
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2.7: Dimerization mutant 
We wished to determine the extent to which decreased MRE11-NBS1 interaction could be 
caused by disruption of the NBS1 binding site across the MRE11 homodimer interface. To ablate 
this binding site, an MRE11 homodimerization mutant (DM) was made. MRE11 L72 is a highly 
conserved residue – being an aliphatic hydrophobic residue in eukarya and prokarya (Figure 
17A) – located at the MRE11 homodimer interface where loop α2-β3 packs against helix H2 of 
the opposite protomer [59]. Along with the latching loops, this residue participates in formation 
of a hydrophobic pocket (Figure 17B). MRE11 L72D was designed to perturb this hydrophobic 
pocket and thereby disrupt MRE11 homodimerization and NBS1 binding across the latching 
loops. 
Yeast two-hybrid was used as before to assess DM homodimerization and direct interaction with 
NBS1 (Figure 17C-F). DM homodimerization was substantially impaired. Hence, MRE11 L72D 
is the first mammalian homodimerization mutant described. DM interaction with NBS1 was also 
impaired. These results are consistent with L72D disrupting NBS1 binding across the latching 
loops.  
Notably, DM showed a similar degree of NBS1 binding deficiency as ATLD17. These results are 
consistent with ablation of the same NBS1 binding site on DM and ATLD17. The mutant residue 
in ATLD17, W243, is highly conserved and is near Mn
2+
-coordinating residues important for 
MRE11 folding [59,73]. Hence, W243R might result in local misfolding and thereby disrupt the 
latching loop-mediated homodimerization and NBS1 binding. The other NBS1 binding sites 
could remain intact in this scenario explaining why NBS1 binding is only partially disrupted. 
This disruption of ATLD17-NBS1 interaction, in turn, could cause ATLD17 to be defective in 
facilitating ATM activation and activity.  
 
Results are summarized in Tables 3 and 4. 
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Figure 17: Dimerization mutant 
(A) MRE11 stick diagram and alignment showing L72, the residue changed in the DM. (B) 
HsMRE11 phosphodiesterase domain dimer showing L72 (pink), W243 (violet), and residues 
340-366 (mocha). One MRE11 protomer is depicted as light gray while the other is light blue. 
Note that the latching loops in these structures were mostly disordered and therefore are not 
shown. The two images shown are rotated ~90° about the long axis of M2 from each other. (C) 
DM homodimerization was similar to background by yeast two-hybrid colorimetric assay. (D) 
Y2H colony growth assay revealed substantially abrogated DM homodimerization. (E) Direct 
interaction between DM and NBS1 was reduced by 59% compared to wild-type by α-
galactosidase assay. (F) DM-NBS1 interaction was slightly but reproducibly reduced by Y2H 
colony growth assay. 
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Table 3: A summary of kinase activity findings 
 
Table 4: A summary of MRE11/RAD50/NBS1 complex integrity results 
 
 
  
assay ATLD17 ASM GRM ATLD1
pATM induction + ND ++++ ND
pKAP1 induction + <+ +++ ++++
G2/M checkpoint ++++ ++ ++++ ++++
ATR 
activity
pCHK1 induction ++++ + + ++++
mutant
ATM 
activity
symbol + ++ +++ ++++ ND
% of wild-type [12.5%,37.5%) [37.5%,62.5%) [62.5%,87.5%) [87.5%,112.5%) not determined
method DM ATLD17 ASM GRM ATLD1
homodimerization Y2H <+ ++ <+ ++++ ++++
molar ratios ND ++++ ++++ ++++ ++++
coIP ND +++ ++ ++++ ND
molar ratios ND ++ ++ ++++ ++++
Y2H ++ ++ <+ ++++ ++++
coIP ND ≥++ ≥++ ++++ ND
RAD50 interaction 
NBS1 interaction
mutant
symbol + ++ +++ ++++ ND
% of wild-type [12.5%,37.5%) [37.5%,62.5%) [62.5%,87.5%) [87.5%,112.5%) not determined
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CHAPTER 3: DISCUSSION 
 
3.1: Roles of mutants in carcinogenesis 
Here we have shown ATLD17, ASM, and GRM - even when expressed to physiologic MRE11 
levels - to exhibit defects in facilitating IR-induced apical kinase activity (Figure 18A-C). For 
ATLD17 and ASM, the defects appeared to reflect varying degrees of abrogation of MRN 
complex stability. In contrast, though ATLD1 was previously associated with defects in apical 
kinase activity [165], ATLD1 expression to physiologic MRE11 levels complemented apical 
kinase activity. This characterization is the first of any kind for ASM, GRM, or a mammalian 
MRE11 homodimerization mutant. In addition, we were the first to describe ATLD17 in the 
context of physiologic MRE11 levels. Finally, no prior reports had been made regarding the 
effects of ATLD1 expressed to physiologic MRE11 levels on ATR activity or cell cycle 
checkpoint function. 
Though ATLD17 patient cell lines displayed defects in IR-induced ATM activation, they also 
possessed reduced MRE11 levels [132]. Hence, our study is the first to show ATM activity 
defects in ATLD17-expressing mammalian cells to be due to ATLD17 hypomorphism per se. S. 
pombe were engineered to express SpMre11 W248R, a mutant analogous to ATLD17 [217]. This 
mutant was not found to be defective in facilitating the activity of Tel1, the S.pombe ATM 
orthologue, but it did have a defect in facilitating Chk1 phosphorylation. These findings in 
S.pombe were counterintuitive because authors of the same study found dramatic disruption of 
SpM(ATLD17)RN complex stability and decreased cellular complex component levels, and in 
mammals, ATM activation is known to rely upon intact MRN [215]. Evolutionary divergence in 
MRN function could explain the discrepancies between yeast and mammalian ATLD17 findings.  
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Figure 18: Model depicting ionizing radiation-induced apical kinase activity in mutant-
expressing cells 
Schematics are shown for cells expressing ATLD17 (A), ASM (B), or GRM (C). Thick arrows 
represent normal flux whereas thin arrows represent suspected deficiency. 
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Due to the decreased NBS1 levels in ATLD17 cells and disrupted ATLD17-NBS1 interaction, 
ATLD17 is likely more cytoplasmic than wild-type MRE11. However, because some ATM-
dependent events were observed and events downstream of DNA resection did not appear 
deficient, enough ATLD17 seemed to get to the nucleus to exert its functions on DNA resection 
and ATR activation. The result was cells that appeared to have suboptimal DSBR yet could 
possibly avoid mitotic catastrophe by G2/M checkpoint activation following DNA damage. 
Further study of ATLD17 subcellular distribution is merited to discern this mechanism more 
accurately.  
Whether ATLD17 is effective in aiding homologous recombination (HR) or alternative end-
joining (A-EJ) remains to be seen. If ATLD17 alters the balance of pathway choice, it could have 
myriad effects. Error-prone A-EJ has been associated with both tumor-promoting translocations 
and tumor-maintaining DNA repair [187,188,219-226]. Hence, a tipping of the balance in favor 
of A-EJ could enable a mutator phenotype in which DSB repair proceeds efficiently enough to 
allow for continued proliferation. A-EJ inhibitors, such as PARP inhibitors, could prove to be 
synthetic lethal to such malignancies. On the other hand, tipping the balance in favor of HR 
would necessitate a distinct set of therapeutic choices and targeting strategies. Regardless of 
ATLD17’s effects on pathway choice, one potential chemopreventative or chemotherapeutic 
strategy would be to design small molecules that stabilize MRE11-NBS1 interaction to overcome 
ATLD17’s defect. 
Though we did not formally measure protein stability, our observations are consistent with ASM 
being an unstable protein. Despite our attempts to drive expression of each mutant to physiologic 
MRE11 levels, we had lower yield in obtaining MEFs expressing ASM to at least physiologic 
MRE11 levels than we had with any other mutant discussed presently (data not shown). 
Additionally, those clones that did appear to express ASM did so at lower levels and for 
substantially fewer passages under selection compared to cells expressing other mutants (data not 
shown). Notably, other investigators have describe cells and tissues of patients with an MRE11A 
allele encoding MRE11A
ASM
 mRNA, and they showed no evidence that they detected ASM 
protein [129,139]. All together, these results suggest that ASM is misfolded, unstable, and/or 
dysfunctional to the extent that it contributes little to MRE11 function.  
 51 
 
Because ASM was not detected in MRE11A
ATLD17/ASM
 patient cells or tissues [129,139], 
ATLD17 likely predominates in these patients’ cells. ATLD17 failed to completely complement 
NBS1 levels, to complex with NBS1 optimally, and to efficiently facilitate ATM activation. 
Hence, ATLD17 appeared to impose NBS1 dysfunction, which could explain why ATLD17 
patients exhibited an NBS phenotype, namely cancer predisposition. This notion is supported by 
the observation that some ATLD patients with a mutant defective in NBS1 interaction, MRE11 
W210C, were microcephalic, another phenotype typically associated with NBS and not ATLD 
[128]. 
Unlike ATLD17 and ASM, GRM appeared to form stable MRN complexes and capable of 
facilitating ATM activation and activity similarly to wild-type MRE11. However, GRM did 
display a defect in facilitating ATR activity. This could reflect a defect in any one of several 
steps in DNA end processing: MRN DNA binding, MRE11 nuclease activity, CTIP/BRCA1 
recruitment, recruitment of other nucleases, etc…. An MRE11 mutant in which nine glycine-
arginine-rich motif arginine residues have been changed to lysine residues, MRE11 RK, was also 
defective in ATR activity following IR treatment [65]. In addition, MRE11 RK was found to be 
defective in DNA binding and exonuclease function, which were proposed to result in defective 
end-processing and ATR loading and activity. GRM could be qualitatively similar in its defects 
though, given the more subtle nature of amino acid residue substitution in GRM, the defects 
would be expected to be more subtle. 
Given MRE11 RK DNA binding and exonuclease defects, R572Q could cause a defect in end 
processing. The lymphoma in which GRM was found was only heterozygous mutant [205]. 
Therefore, if GRM contributed to lymphomagenesis, it could have been through reduced MRE11 
function and/or dominant-negative effects. The former possibility is supported by the observation 
that ATLD1 heterozygosity, which is associated with ~50% of physiologic MRE11 levels, has 
also been associated with malignancy [207]. A counter argument can be made based on the 
observation that Mre11a
+/Δ
 mice do not appear to be cancer predisposed. A dominant negative 
effect of GRM is easy to imagine. GRM was able to interact well with wild-type MRE11. 
Moreover, even the more severe MRE11 RK mutant was able to localize to DNA damage, 
suggesting that GRM might as well [65]. In sum, this data suggests that GRM could complex 
with wild-type MRE11 and localize to sites of DNA damage where GRM then might disrupt 
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DNA end processing. Defective end processing could favor lower-fidelity A-EJ pathways, which 
require less end processing than HR. Another interesting possibility is that R572Q disrupts 
MRE11 interaction with the mismatch repair protein mutL homolog (MLH) 1. R572 lies within 
the MRE11 452-632 motif, which was identified as being important for this interaction [227]. 
Disruption of MRE11-MLH1 interaction has been linked to defective mismatch repair [228,229]. 
Also, R572 lies in the C-terminal uncrystallized portion of MRE11. Recent work shows that the 
C-terminal-most 76 amino acid residues interact with CDK2, and other MRE11 residues might 
modulate MRE11-CDK2 interaction [69]. Alteration of this interaction in such a way that CDK2 
interaction is enhanced could conceivably contribute to aberrant proliferation. 
The MRN/CTIP/BRCA1 complex is important for cell cycle-dependent regulation of DNA 
resection and HR [69,115]. Central to the regulation of this complex is CDK-mediated CTIP 
phosphorylation during the S and G2 phases of the cell cycle. In the presence of DSBs, ATM 
mediates further CTIP phosphorylation. Only upon CDK- and ATM-mediated phosphorylation 
does CTIP properly promote DNA resection and HR. Hence, mutant-associated alteration of 
CDK or ATM activity could disrupt this complex and thereby alter DSB repair pathway choice. 
In fact, most of the mutants discussed presently appear(ed) to affect one of these activities. 
ATLD1 fails to enable CDK2-mediated CTIP phosphorylation, which has been shown to result 
in MRN/CTIP/BRCA1 complex disruption [69]; ATLD17 and ASM were each defective in IR-
induced ATM activity. Though still speculative, GRM could plausibly be defective in enabling 
CDK2 activity towards CTIP as ATLD1 is. Indeed, MRN/CTIP/BRCA1 complex disruption is 
potentially a mechanism by which several cancer-associated MRE11A mutations contribute to 
carcinogenesis. Further study of these mutants’ effects on CTIP phosphorylation, HR efficiency, 
and DSB repair pathway choice is requisite to better understanding of how these mutants might 
mediate oncogenesis. 
Cancer-associated MRE11A mutations could alter MRE11 interaction with still other MRE11 
interactors. An unbiased screen of MRE11 wild-type and mutant interactors could identify the 
full range of interactions disrupted by MRE11A mutation. Besides other well-recognized 
mediators of DSB repair, cell cycle machinery and mismatch repair proteins would be of special 
interest.  
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Our study has several limitations. Firstly, we used SV40 large T antigen immortalized cells; 
therefore, any mutant-associated defects in p53 activity were not appreciated [230-232]. 
Moreover, other mutant defects that are p53 function-dependent were not observable using this 
system. Secondly, we used murine embryonic fibroblasts rather than cells of the tissues which 
gave rise to patient malignancies. Therefore, tissue-specific splicing, DNA damage repair 
pathway choice, etc… could not be taken into account. Finally, we transduced our cells using an 
adenoviral vector. Adenoviral proteins have been shown to interfere with and degrade multiple 
DNA repair components, including MRN [233,234]. To minimize experimental artifacts due to 
adenoviral protein interference, we allowed several days between replication-defective adeno-cre 
treatment and our experiments. Nonetheless, it remains possible that adenoviral proteins still 
caused experimental artifacts. For these reasons and more, murine models could prove to be 
invaluable for further understanding of the roles of ATLD17, ASM, and GRM in oncogenesis. 
Ultimately, because MRN and ATM display differences in function between mice and humans 
[235,236], it would be beneficial to reproduce cell-based and in vitro studies using human cells 
and human proteins.  
Nonetheless, our results suggest MRE11 mutants contribute to carcinogenesis through several 
distinct mechanisms. ATLD17, ASM, GRM, and ATLD1 each had unique effects on apical 
kinase activity and MRN complex stability. ATLD17 and GRM exhibited slight defects in 
facilitating apical kinase activity perhaps reflecting localized protein misfolding or defective 
DNA end processing, respectively. Despite the suboptimal DSBR, each of these mutants 
appeared to support proliferation and G2/M checkpoint function. ASM, on the other hand, 
seemed grossly dysfunctional. Because GRM appeared competent in MRN complex formation 
and deficient in facilitating MRN-dependent events, GRM could exert a dominant negative effect 
on wild-type MRE11. Therefore, MRE11A
ATLD17/ASM
 and MRE11A
+/GRM
 cells could possess a 
mutator phenotype. In contrast, ATLD1 could broadly support apical kinase activation but is 
largely absent from MRE11A
ATLD1/ATLD1
 cells. Thus, MRE11A
ATLD1
 carriers could be cancer-
predisposed due to MRE11 haploinsufficiency.  
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3.2: Insights into structure-function relationships 
Our findings are consistent with the MRE11 capping domain being important for nuclease 
domain folding and stability. Disruption of the capping domain by deletion of 27 amino acid 
residues in ASM was accompanied by disruption of every aspect of MRN complex formation 
and apical kinase activation tested. In unicellular organism MRE11 orthologues, the capping 
domain has DNA-, RAD50-, and NBS1-binding sites; however, the capping domain is not 
directly involved in MRE11 homodimerization [62,63,67,68,73]. Here, we found a capping 
domain deletion to affect homodimerization in the nuclease domain, even in the absence of 
RAD50 and NBS1. Therefore, the capping domain appears to be important for folding of the 
greater phosphodiesterase domain. Other investigators have described patient cells with an allele 
encoding MRE11A
ASM
 mRNA; however, they found no evidence of ASM protein [129,139]. 
Hence, the capping domain appears to be important for phosphodiesterase domain folding and 
protein stability. 
Study of ATLD17 supported the notion that the MRE11 nuclease domain plays an important role 
in ATM activation and activity. MRE11 catalytic domain disruption has been shown to affect 
ATM activation independently of nuclease function [121]. Mirin is an MRE11 exonuclease and 
ATM activation inhibitor [237]. Treatment with mirin did not appear to differentially affect 
ATM activation by wild-type MRN or nuclease-deficient M(H129N)RN [121]. Moreover, 
MRE11 H129N was nuclease dead but still facilitated ATM activation while MRE11 D130V 
was deficient in both nuclease activity and ATM activation. 
S.pombe Nbs1 binding has been shown to affect Mre11 homodimer conformation, DNA repair, 
and telomere maintenance [73]. This could serve as a means by which Nbs1 communicates 
information to Mre11 and thereby affects Mre11 function. By analogy, mammalian NBS1 could 
relay CTIP and MDC1 phosphorylation and binding status through modulation of MRE11 
conformation. CTIP could thereby exert its influences on MRE11 nuclease activity. This 
communication would be expected to be bi-directional. MRE11 homodimer confirmation could 
reflect M2R2 DNA or RAD50 nucleotide binding status which could, in turn, be communicated 
to NBS1 via changes in latching loop conformation. Consistent with this idea, prokaryotic MR 
nucleotide binding status has been shown to influence protein conformation [63,67,68], and 
human RAD50 nucleotide binding status has been shown to influence MR NBS1 binding, MRN 
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DNA binding, and ATM activity [66,121]. Inability of MRE11 to communicate DSB sensing to 
NBS1 could result in defective ATM activation and activity. Alternatively, ATM makes multiple 
contacts on the MRN complex [91], so disruption of ATM-MRE11 interaction itself could affect 
ATM activity. 
Our findings further understanding of the importance of arginine methylation in cellular 
processes. An ever-increasing number of proteins, including components of the pre-mRNA 
splicing, polyadenylation, transcription, signal transduction, and DNA damage response 
machinery, are being found to be subject to arginine methylation [238]. This modification often 
occurs around glycine residues. Clusters of glycines and arginines constitute glycine-arginine-
rich (GAR) motifs, and such motifs are commonly found in nucleic acid binding proteins and are 
especially prone to arginine methylation. GAR motifs and their methylation have been shown to 
affect protein subcellular localization, nucleic acid binding, and protein function [65,166-
168,239-244]. In the case of MRE11, GAR motif arginine methylation appears to influence 
MRE11 protein stability, subnuclear localization, DNA binding, and exonuclease activity 
[65,166,168]. MRE11 in which the GAR motif arginines have been replaced with lysines, 
MRE11 RK, exhibited decreased in vitro binding to dsDNA, ssDNA, and splayed-arm DNA and 
decreased in vitro exonuclease activity towards blunt-ended dsDNA in the context of RAD50 
and NBS1 relative to wild-type MRE11. Replacement of the GAR motif arginines with alanines 
in MRE11 RA further reduced MRE11 exonuclease activity towards and binding of dsDNA. 
Deletion of MRE11 residues 498-615, which includes the MRE11 GAR motif, substantially 
abrogated MRE11 binding of and exonuclease activity on blunt-ended dsDNA. This region was 
intrinsically able to bind DNA in a manner which required methylation of the GAR motif. 
Moreover, MRE11 methylation was required for DNA damage-induced MRE11 movement from 
the nucleoplasm to chromatin, and MRE11 RK was defective in IR-induced CHK1 
phosphorylation. All together, these results suggest that the MRE11 GAR motif is required for 
optimal MRE11 DNA binding and that disruption of the methylation or charge of the GAR 
motif, in turn, disrupts MRE11 localization to DSBs, DNA end resection, and checkpoint kinase 
activation. Our results are consistent with these conclusions and go further to suggest that even a 
subtle disruption of GAR motif methylation or charge is sufficient to affect these processes. 
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GAR motifs can be found in other proteins involved in maintenance of genomic stability, 
including p53 binding protein 1 (53BP1) and telomere repeat factor (TRF) 2. 53BP1 plays 
important roles in facilitating non-homologous end-joining and suppressing resection of DNA 
ends [241,245-247]. Substitutions of 53BP1 GAR motif arginines with lysines or alanines 
yielded 53BP1 RK or 53BP1 RA, respectively, and disrupted 53BP1 DNA binding in vitro 
[239,240]. Despite these DNA binding defects, the 53BP1 GAR motif is not essential for 
shelterin dysfunction-associated telomeric fusion; 53BP1 RK and 53BP1 ΔGAR mutants 
complemented shelterin dysfunction-associated telomeric fusion to 80% of wild-type levels 
whereas complete loss of 53BP1 reduced the frequency of such fusion events to less than 10% of 
wild-type levels [241,242]. The DNA binding defect of 53BP1 RK is not reflected by defects in 
53BP1-facilitated class switch recombination either; 53BP1 RK was able to support 53BP1 
functions in class switch recombination [245]. Indeed, though the 53BP1 GAR motif appeared 
important for DNA binding in vitro, it appears to be largely dispensable for 53BP1 function in 
promoting NHEJ and preventing CTIP-mediated DNA end resection.  
TRF2 is a component of the telomeric repeat-binding shelterin complex crucial for protection of 
telomeres against aberrant DNA repair processes [248]. In contrast to the largely negative results 
observed for the 53BP1 GAR motif to date, TRF2 RK expression resulted in telomere 
deprotection and fusion [243]. The TRF2 GAR motif might be required for TRF2 interaction 
with telomere-repeat-encoding RNA (TERRA) and recruitment of the origin recognition 
complex (ORC) to telomeres [244]. This complex could facilitate timely replication of telomeres 
and help modulate telomeric chromatin compaction. Hence, subtle alterations of the TRF2 GAR 
motif like that seen for the MRE11 GAR motif in the GRM mutant could potentially affect 
telomere integrity, chromosomal stability, and cellular viability. 
Unlike the other motifs studied, the CDK2 interacting motif was not required for stable MRN 
complex formation, apical kinase activity, or G2/M checkpoint activation. Hence, MRE11-
enabled CDK2 activity toward CTIP appeared dispensable for these functions. In contrast with 
our findings, the MRE11 C-terminus was required for ATM activity in biochemical assays [91]. 
It could be that the C-terminus is essential for directing ATM activity towards certain substrates. 
However, this requirement could be masked in cells by as yet unidentified compensatory 
mechanisms. 
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More broadly, our results point to the complexity and delicacy of protein complex regulation in 
vivo. Links between even subtle changes in essential proteins and human pathology should be 
carefully studied. Catalytic domain mutations might actually exert their pathogenic influences 
through alterations of protein-protein interactions. Kinase activation can be indirectly controlled 
via subtle conformational changes in protein sensors. Glycine-arginine-rich motifs are found on 
many proteins, methylated arginines on many more, and post-translational modifications abound 
in the proteome, and their control over protein function is evident here. Given the prevalence and 
centrality of protein environmental sensors, protein-protein communication through subtle 
conformational modulation, kinase regulation, and post-translational modification to life, the 
protein physiology and pathophysiology studied here may very well translate to elsewhere in the 
human proteome and mutatome. We hope our efforts inform future discernment of these 
fundamental processes. 
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CHAPTER 4: MATERIALS AND METHODS 
 
DNA construct creation 
Select Mre11a mutations were introduced into pEF6-MmMre11a using site-directed mutagenesis 
(Stratagene) or – for the alternative splice mutant – PCR amplification followed by ligation. 
These mutants were shuttled into pGBKT7 and pGADT7 (Clontech).  MmNbn (GeneCopoeia) 
was TOPO PCR subcloned (Life Technologies) and shuttled into the Y2H vectors. 
MEF engineering and culture 
Mre11a
cond/Δ
 murine embryonic cell lines [76] were maintained using standard culture 
conditions. Cells were stably transfected with wild-type- or mutant-expressing pEF6-MmMre11a 
per manufacturer’s instructions (Lipofectamine 2000, Life Technologies). Briefly, cells were 
grown to 50-90% confluency in six-well plates. Cells were treated with 10 µl lipofectamine 2000 
transfection reagent and 2.5-10 µg pEF6-MmMre11a in 2.5 ml serum- and antibiotic-free 
medium per well. Twenty-four hours post-transfection, cells were split; they were seeded at 
3200-200 cells per six-well plate well. Forty-eight hours post-transfection, the cells were treated 
with 5-10 µg/ml blasticidin. Blasticidin-containing medium was subsequently refreshed every 
two days. Four days post-transfection, it was decided whether the cells were seeded sparsely 
enough to allow for clonal isolation. Where that appeared to be the case, colonies were allowed 
to grow to confluency at which time they were picked using a pipette tip and seeded into a 
twenty-four-well plate well with blasticidin-containing medium.  
Prior to each experiment, cells were grown under blasticidin selection for three days, split 
(seeded at a density of 5x10
5
 cells per 10 cm plate), allowed to recover for a day, treated with 
replication-defective adeno-cre (University of Michigan Vector Core; 3 µl adeno-cre and 5 ml 
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medium per 10 cm plate), allowed to recover for two days (in the presence of complete medium), 
split (seeded at a density of 5-7.5x10
5
 cells per 10 cm plate), and allowed to recover for two-
three days after which time experiments were performed. Where ionizing radiation treatment is 
indicated, slightly subconfluent cells were exposed to a 
137
Cs source. 
Mre11a RNA typing 
5e5 cells per sample were pelleted, and RNA was isolated (AllPrep DNA/RNA Mini Kit, 
Qiagen). RNA concentration was determined by Nanodrop. RT-PCR was performed with the 
following specifications: forward primer: GCAATCTCAACATTTCCATTCC, reverse primer: 
GTTTCTTCTTGGGCAACTACTG; 200 ng RNA per reaction; Platinum Taq with or without 
Superscript III reverse transcriptase (Life Technologies) was used per manufacturer’s protocol; 
PCR program: 55°C for 30 minutes, 94°C for 2 minutes, 94°C for 15 seconds, 59°C for 30 
seconds, 68°C for 3.5 minutes, back to step 3 39 times, and 68°C for 7 minutes. Amplicons were 
run on an agarose gel or subjected to Sanger sequencing (sequencing primers: 
CAGTATTTAGTATCCACGGCAAC, CATCGTCATCATCCTCATCTG, 
GGAGAAGAGATCAACTTTGGG, and CTCTTCCTTGTCCACAAACTC). 
Immunoblot 
Cells were lysed in Laemmli buffer (BioRad; 200-300 µl 1:1 2x buffer:1x PBS per 10 cm plate) 
and heated at 100°C for 10 minutes. Protein concentrations were ascertained by BCA assay 
(Thermo Scientific). Beta-mercaptoethanol was then added to the samples to a final 
concentration of 2.5%. Proteins were resolved by SDS-PAGE (4% polyacrylamide stacking gels; 
6% polyacrylamide separation gels were used if probing for pATM; otherwise, 8% 
polyacrylamide separation gels were fine), transferred (for 20-24 hours at 25V in 20% methanol-
containing transfer buffer (National Diagnostics) or for 2-2.5 hours at 25V in 10% methanol-
containing transfer buffer) to PVDF membranes (Immobilon), and blocked in 5% milk TBST (25 
mM Tris-Cl, 150 mM NaCl, 0.05% tween-20, pH 7.6). Primary antibodies used were as follows: 
MRE11 (Cell Signaling 4895, 1:1000 in 5% BSA TBST for 16-20 hours), RAD50 (Bethyl A300-
184A, 1:500 in 3% milk TBST for two days), NBS1 (Novus NB110-57272, 1:500 in 3% milk 
TBST for two days), pATM S1987 (Rockland 200-301-400, 1:500 in 3% milk TBST for 2-4 
days), ATM (Cell Signaling 2873, 1:1000 in 5% BSA TBST for two days), pKAP1 (Bethyl 
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A300-767A, 1:2500 in 3% milk TBST for 1-2 days), KAP1 (Cell Signaling 4124, 1:1000 in 5% 
BSA TBST for 2 days), pCHK1 S345 (Cell Signaling 2341, 1:500 in 5% BSA TBST for two 
days), CHK1 (Cell Signaling 2360, 1:1000 in 3% milk TBST for two days), GAPDH (Abcam 
ab8245, 1:4000 in 5% milk TBST for 1.5 hours to overnight), HA-tag (Cell Signaling 2367, 
1:1000 in 5% milk TBST overnight), MYC-tag (Cell Signaling 2278, 1:1000 in 5% BSA TBST 
overnight), and tubulin (Pierce MA1-80017, 1:1000 in TBST overnight). Either fluorophore (Li-
Cor, 1:4000-1:2000 in 3-5% milk TBST for 1.5 hours to overnight)- or peroxidase (Jackson 
Immunolabs, 1:2000 in 3-5% milk TBST for 1.5 hours)-conjugated secondary antibodies were 
used. When called for, membranes were stripped for 30-60 minutes at room temperature 
(stripping buffer recipe: 60 ml 0.5M Tris-HCl pH 6.8, 3.5 ml of β-mercaptoethanol, 50 ml of 
20% SDS, and 386.5 ml of ultrapure water), rinsed, and reblocked with 5% milk TBST prior to 
being reprobed. Quantitation was performed following the use of Li-Cor secondaries. 
G2/M checkpoint 
7.5e5 cells were plated per 10 cm dish, grown for 48 hours, treated with 10 Gy IR from a 
137
Cs 
source or mock treated, allowed to recover for an hour, and fixed. Cells were probed for the 
mitotic marker p-histone H3 S10 [214] using Cell Signaling primary antibody and FITC 
conjugated secondary antibody (BD Pharmingen). Flow cytometry (Accuri C6, BD Biosciences) 
was performed as described previously [249]. 
Immunoprecipitation 
10-20 million cells per 14.5-cm plate were lysed with 300 µl 50mM TrisCl, 300mM NaCl, 10% 
glycerol, and 1% NP-40. Lysates were precleared with protein A agarose beads (Roche); lysate 
protein concentrations were measured by BCA assay (Thermo Scientific); 20 µg/µl protein 
solutions were made; beads were incubated with either anti-MRE11 antibody (Cell Signaling), 
anti-RAD50 antibody (Bethyl), or anti-NBS1 antibody (Novus); and 0.5 mg protein was added 
along with phosphatase and protease inhibitors (Roche). After an overnight incubation, beads 
were washed four times. Proteins were eluted from the beads with Laemmli buffer (BioRad), and 
extracts were heated at 95°C for 10 minutes. 
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Yeast two-hybrid 
Y2HGold (Clontech) were cotransformed using the Yeastmaker Yeast Transformation system 
(Clontech) per the manufacturer’s protocol. To select for cotransformed cells, transformation 
reactions were plated onto SD-L-W agar (Clontech) plates, and colonies were picked and 
streaked onto SD-L-W agar plates. To test for interaction by colorimetric assay, the restreaked 
yeast were picked, grown in SD-L-W (Clontech) overnight, assessed for their density (by 
OD600nm), and briefly centrifuged. 16 µl of supernatant was aliquoted per reaction, 48 µl assay 
buffer (2 volumes 0.5M NaOAc, pH 4.5 (aq) and 1 volume 100mM p-nitrophenyl-α-D-
galactopyranoside (Sigma-Aldrich) (aq)) was added, and the reactions were incubated at least 
overnight. Each reaction was quenched with 136 µl 1M Na2CO3 (aq), and OD410nm readings were 
taken by microplate reader. Colony growth was assessed by culturing yeast overnight, 
normalizing yeast density by OD600nm, and plating five 10X serial dilutions onto SD-L-W 
(loading control) and SD-L-W-H-ade (interaction test) agar plates.  
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